You are cordially invited to attend the 2026 Annual Meeting of Stockholders of Lantronix, Inc., a Delaware corporation, which will be held at our corporate headquarters located at 48 Discovery, Suite 250, Irvine, California 92618, on November 3, 2026, at 9:00 a.m. Pacific time.

Details of the business to be conducted at the annual meeting are included in the accompanying Notice of 2026 Annual Meeting of Stockholders and Proxy Statement.

It is important that your shares be represented at the annual meeting and voted in accordance with your instructions. Whether or not you plan to attend the meeting, we urge you to submit your proxy or voting instructions as promptly as possible so that your shares will be voted at the meeting. This will not limit your right to vote in person or to attend the meeting.

We look forward to seeing you at the upcoming annual meeting.

The 2026 Annual Meeting of Stockholders for Lantronix, Inc., a Delaware corporation, will be held at our corporate headquarters located at 48 Discovery, Suite 250, Irvine, California 92618, on November 3, 2026, at 9:00 a.m. Pacific time, for the following purposes:

The foregoing proposals are more fully described in the annual meeting proxy statement. Stockholders of record who owned our common stock at the close of business on September 8, 2026, are entitled to attend and vote at the annual meeting.

The board of directors recommends that you vote your shares “FOR” each director nominee named in Proposal 1, and “FOR” Proposals 2, 3 and 4.

Your vote is very important. Whether or not you expect to attend the annual meeting, please submit your proxy or voting instructions as promptly as possible in order to ensure your shares are represented at the annual meeting. Even if you have voted by proxy, you may still vote in person at the annual meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote in person at the annual meeting, you must obtain a proxy issued in your name from the broker, bank or other nominee that holds your shares.

We cordially invite you to attend the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) for Lantronix, Inc. (sometimes referred to as, the “Company,” “we,” “us,” or “our”). The Annual Meeting will be held at 9:00 a.m. Pacific time on November 3, 2026, at the Company’s corporate headquarters, located at 48 Discovery, Suite 250, Irvine, California 92618.

This proxy statement is being furnished by and on behalf of our board of directors (the “Board”) in connection with the solicitation of proxies to be voted at the Annual Meeting. This proxy statement describes issues on which the Company is asking you, as a stockholder, to vote and provides information that will allow you to make an informed voting decision.

The approximate date on which this proxy statement and the enclosed form of proxy are first being sent or given to stockholders of record is September 22, 2026. If you hold your shares through a broker, bank or other nominee, this proxy statement and a voting instruction form are being forwarded to you by such broker, bank or other nominee.

References in this proxy statement to fiscal years refer to the fiscal year ended June 30 of the referenced year. For example, “fiscal 2025” refers to the fiscal year ended June 30, 2025, “fiscal 2026” refers to the fiscal year ended June 30, 2026, and “fiscal 2027” refers to the fiscal year ending June 30, 2027.

This proxy statement and our Annual Report on Form 10-K for fiscal year 2026 are available on the Internet at www.proxyvote.com by using the control number provided on your Notice or proxy card (if you received a printed copy of the proxy materials). You can also view the proxy materials on our website at www.lantronix.com. Stockholders may also request a printed set of the proxy materials by following the instructions in the Notice of Internet Availability.

The following questions and answers are intended to briefly address potential questions regarding this proxy statement and the Annual Meeting. They are also intended to provide our stockholders with certain information that is required to be provided under the rules and regulations of the Securities and Exchange Commission (the “SEC”). These questions and answers may not address all of the questions that are important to you as a stockholder. If you have additional questions about the proxy statement or the Annual Meeting, please contact our Corporate Secretary using the contact information provided in this proxy statement.

The date, time and place of the Annual Meeting are:

You are entitled to vote your shares of common stock if you were the owner of the shares as of the close of business on September 8, 2026 (the “Record Date”). As of the Record Date, there were a total of 46,879,400 shares of our common stock outstanding and entitled to vote at the Annual Meeting. You are entitled to one vote for each share of common stock that you own.

We sent you the Notice of Internet Availability of Proxy Materials (the “Notice”) because our Board is soliciting your proxy to vote at our Annual Meeting, including at any postponements or adjournments of the meeting. We have elected to provide access to the full proxy materials over the Internet and have provided our stockholders with

instructions on how to access the proxy materials in the Notice that you received. Rules adopted by the Securities and Exchange Commission (the “SEC”) allow us to provide access to our proxy materials over the Internet. All stockholders will have the ability to access the proxy materials on the website at www.proxyvote.com or may request a printed set of the proxy materials. Instructions on how to access the proxy materials or to request a printed copy may be found in the Notice. We intend to furnish the Notice to all stockholders of record entitled to vote at the Annual Meeting on or about September 22, 2026.

The only matters we currently expect will be voted on at the Annual Meeting are the following proposals, which are described in this proxy statement:

If other matters are properly presented at the Annual Meeting, the holders of any proxies you have properly submitted will vote your shares in their discretion.

We will convene the Annual Meeting if stockholders representing the required quorum of shares of common stock either sign and return a proxy card or voting instruction form, vote through the Internet or by telephone, or attend the meeting in person. A majority of the shares of our issued and outstanding common stock entitled to vote at the Annual Meeting present in person or represented by proxy will constitute a quorum. If you sign and return a proxy card or voting instruction form or vote through the Internet or by telephone, your shares will be counted in determining whether a quorum is present at the Annual Meeting even if you abstain from voting on any of the proposals. In addition, if you hold your shares in street name (i.e., through a broker, bank or other nominee), your shares may also be counted for purposes of determining whether a quorum is present at the Annual Meeting even if you do not submit voting instructions to your broker. See “How are broker non-votes treated?” below.

If you hold your shares in street name through a brokerage account and you do not submit voting instructions to your broker, your broker has authority under New York Stock Exchange rules applicable to brokers to vote your shares in its discretion on certain “routine” matters. However, a broker cannot vote shares held in street name on non-routine matters unless the broker receives voting instructions from the street name holder. Proposal 2 relating to the ratification of the appointment of our independent registered public accountants is considered a “routine” matter. Accordingly, your shares may be voted on Proposal 2 if they are held in the name of a broker, even if you do not provide the broker with voting instructions. Proposal 1 relating to the election of five directors to the Board and Proposals 3 and 4 relating to the advisory vote on compensation of our named executive officers and the amendment to our 2020 Performance Incentive Plan, respectively, are considered “non-routine” matters. Therefore, if you hold your shares in street name through a brokerage account and you do not submit voting instructions to your broker, and your broker exercises its discretion to vote on Proposal 2, your shares will be counted as present and entitled to vote for the purpose of determining the presence of a quorum at the Annual Meeting and will be voted on Proposal 2 in the manner directed by your broker, but your shares will constitute “broker non-votes” on each of Proposals 1, 3 and 4 at the Annual Meeting.

For Proposal 1, you may vote “FOR” or “AGAINST” each director nominee, or you may abstain from voting. A director nominee must receive the affirmative vote of a majority of the votes cast with respect to that nominee to be elected. In other words, the number of shares voted “FOR” a director nominee must exceed the number of shares voted

“AGAINST” that nominee’s election. For purposes of the election of directors, abstentions and broker non-votes will not be treated as votes cast and will not be counted in determining the outcome of a director’s election. Stockholders are not permitted to cumulate their shares for the purpose of electing directors.

Pursuant to the procedures established by the Corporate Governance and Nominating Committee of the Board, each incumbent director has submitted to the Chair of the Corporate Governance and Nominating Committee in writing such director’s irrevocable resignation which will be effective upon (1) the failure of such director to receive the required vote at any annual or special meeting at which such director is nominated for re-election and (2) Board acceptance of the resignation. If a nominee fails to receive a majority of the votes cast in the director election, the Corporate Governance and Nominating Committee will make a recommendation to the Board whether to accept or reject the director’s resignation and whether any other action should be taken. If a director’s resignation is not accepted, that director will continue to serve until our next annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier resignation or removal. If the Board accepts the director’s resignation, it may, in its sole discretion, either fill the resulting vacancy or decrease the size of the Board to eliminate the vacancy.

For each of Proposals 2, 3 and 4, you may vote “FOR” or “AGAINST,” or you may abstain from voting. Approval of Proposals 2, 3 and 4 will require the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting and entitled to vote thereon. For purposes of Proposals 2, 3 and 4, abstentions will be treated as shares present in person or represented by proxy and entitled to vote on the matter at the Annual Meeting, so abstaining will have the same effect as voting against the proposal. Broker non-votes will not be counted in determining the outcome of Proposals 3 and 4. There are not expected to be any broker non-votes on Proposal 2. See “How are broker non-votes treated?” above.

The procedures for voting are described below, based upon your form of ownership.

If you are a stockholder of record as of the Record Date, you may vote in person at the Annual Meeting. We will give you a ballot when you arrive.

If you do not wish to vote in person or you will not be attending the Annual Meeting, you may vote by proxy using a proxy card (if you received a printed copy of the proxy materials), through the Internet or by telephone. The procedures for voting by proxy are as follows:

If you hold shares as a stockholder of record and choose to vote by mail, your proxy card must be received before the commencement of voting at the Annual Meeting. If you choose to vote your shares electronically via the Internet or by telephone, your vote by proxy must be received prior to 11:59 p.m. Eastern time on November 2, 2026, the day before the Annual Meeting.

If you are a beneficial owner of shares registered in the name of your broker, bank or other nominee, the organization that holds your shares should have forwarded you a voting instruction form with these proxy materials. To

ensure that your vote is counted, please follow the instructions provided by your broker, bank or other nominee. To vote in person at the Annual Meeting, you must obtain a legal proxy from your broker, bank or other nominee in whose name the shares are registered.

The Board recommends that you vote your shares “FOR” each of the nominees for election to the Board named in Proposal 1, and “FOR” Proposals 2, 3 and 4.

Yes. If you are a stockholder of record, you can change your vote at any time before the vote on a proposal by:

Your attendance at the Annual Meeting will not, by itself, revoke a proxy previously given by you. We will honor the proxy card or authorization with the latest date.

You may send your proxy revocation notice to Lantronix, Inc., 48 Discovery, Suite 250, Irvine, California 92618, Attention: Corporate Secretary. Any proxy revocation notice mailed to Lantronix must be received by our Corporate Secretary on or before 11:59 p.m. Eastern time on November 2, 2026.

If you hold your shares through a broker, bank or other nominee, you must follow the directions and comply with the deadlines received from such broker, bank or other nominee to change any previously submitting voting instructions.

Yes. Although we encourage you to complete and return a proxy card or voting instruction form (if you received a printed copy of the proxy materials) or to vote through the Internet or by telephone to ensure that your vote is counted, you can attend the Annual Meeting and vote your shares in person even if you have submitted a proxy card or voting instruction form or voted through the Internet or by telephone. Voting at the Annual Meeting will have the effect of revoking any prior proxy given by you. If you are a beneficial owner and you want to vote in person at the Annual Meeting, you must first obtain a legal proxy from your broker, bank or other nominee in whose name the shares are registered.

Any proxy that you properly submit and that is not revoked will be voted as you direct. If you are a stockholder of record and you indicate when voting through the Internet or by telephone that you wish to vote as recommended by our Board, or if you sign and return a proxy card without giving specific voting instructions, then the persons you designated as proxy holders will vote your shares:

In the event any director nominee is unable or unwilling for good cause to serve as a director if elected at the Annual Meeting (which is not anticipated), the persons you designate as proxyholders will vote for the election of such person or persons as may be designated by the present Board or the Board may reduce the number of directors on the Board. As to any other business or matters which might otherwise properly come before the Annual Meeting, the proxy holders will vote in accordance with their best judgment. We do not presently know of any such other business.

If you share an address with another stockholder, you will receive only one Notice or set of proxy materials unless you have provided instructions to the contrary. We will promptly deliver, upon oral or written request, a separate Notice or copy of the proxy materials to any stockholder residing at an address to which only one copy was mailed. If you wish to receive a separate Notice or set of proxy materials, please send your request to: Lantronix, Inc., 48 Discovery, Suite 250, Irvine, California 92618, Attention: Corporate Secretary, or contact our Corporate Secretary by phone at (949) 453-3990. You may also contact us if you received multiple Notices or copies of the proxy materials and would prefer to receive a single Notice or copy in the future.

Stockholder Proposals Under Rule 14a-8. In order for a stockholder proposal to be eligible for inclusion in our proxy statement under SEC rules for the 2027 Annual Meeting of Stockholders, the written proposal must be received by our Corporate Secretary at our offices no later than the close of business on May 25, 2027 and must comply with the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Proposals should be addressed to: Lantronix, Inc., 48 Discovery, Suite 250, Irvine, California 92618, Attention: Corporate Secretary.

Stockholder Proposals Under the Company’s Amended and Restated Bylaws. Currently, our Amended and Restated Bylaws (the “Bylaws”) provide that, in order for a stockholder proposal to be submitted at the 2027 Annual Meeting of Stockholders, including nominations for candidates for election as directors, written notice to our Corporate Secretary of such proposal must be received at our principal executive offices:

If the date of the 2027 Annual Meeting of Stockholders is moved more than 30 days before or 70 days after the first anniversary of the Annual Meeting, then notice of a stockholder proposal that is not intended to be included in our proxy statement under Rule 14a-8 under the Exchange Act, must be received no earlier than the close of business 120 days prior to the meeting and not later than the close of business on the later of the following two dates:

Our Bylaws require that a stockholder must provide certain information concerning the proposing person, the nominee and the proposal, as applicable. Nominations and proposals not meeting the requirements set forth in our Bylaws will not be entertained at the 2027 Annual Meeting of Stockholders. Stockholders should contact the Corporate Secretary in writing at 48 Discovery, Suite 250, Irvine, California 92618, to obtain additional information as to the proper form and content of stockholder nominations or proposals.

In addition, a stockholder who intends to solicit proxies in support of director nominees other than the Company’s nominees at the 2027 Annual Meeting of Stockholders must deliver written notice to the Company setting forth the information required by Rule 14a-19 under the Exchange Act no later than September 7, 2027. If we change the date of our 2027 Annual Meeting of Stockholders to a date that is more than 30 calendar days from the first anniversary of this year’s Annual Meeting, the written notice must be received by the later of the 60th day prior to our 2027 Annual Meeting of Stockholders, or the 10th day following the day on which we publicly announce the date of our 2027 Annual Meeting of Stockholders. The notice requirement under Rule 14a-19 is in addition to the applicable notice requirements under our Bylaws as described above.

The stockholder proposal submission requirements set forth in our Bylaws are independent of, and in addition to, the notice requirements under Rule 14a-8, as discussed above, for inclusion of a stockholder proposal in our proxy materials.

The Company does. In addition to sending you these proxy materials, some of our employees may contact you by mail, telephone, facsimile, email or personal solicitation. None of these employees will receive any extra compensation for doing this. We will, at our expense, request brokers and other custodians, nominees and fiduciaries to forward proxy soliciting material to the beneficial owners of shares held of record by such persons.

The Company will announce preliminary voting results with respect to each proposal at the Annual Meeting. In accordance with SEC rules, final voting results will be published in a Current Report on Form 8-K within four business days following the Annual Meeting, unless final results are not known at that time, in which case preliminary voting results will be published within four business days of the Annual Meeting and final voting results will be published once they are known by us.

The Board has established Corporate Governance Guidelines that it follows in matters of corporate governance, which are available on our website at www.lantronix.com, under the “About Us - Investor Relations” section.

The following includes a summary of our Corporate Governance Guidelines and additional information regarding our Board.

The Corporate Governance and Nominating Committee considers candidates for Board membership and recommends director nominees to the Board for consideration and approval. There are no specific minimum qualifications that a director must possess to be nominated. However, the Corporate Governance and Nominating Committee assesses the appropriate skills and characteristics of a nominee based on the size and composition of the existing Board, and based on the nominee’s qualifications, such as: independence from management; depth of understanding of technology, manufacturing, sales and marketing, finance and/or other elements directly relevant to the Company’s business; education and professional background; judgment, skill, integrity and reputation; existing commitments to other businesses as a director, executive or owner; personal conflicts of interest, if any; and diversity of skills, backgrounds, experiences and other qualifications, to meet the Company’s ongoing needs. For more information, see below under the caption “Criteria for Director Nominees.”

No current arrangement or understanding exists between any of our directors, director nominees, or executive officers and any other person, pursuant to which any of them were selected as our director, director nominee, or executive officer.

Our Board currently consists of six directors: James Auker, Saleel Awsare, Sailesh Chittipeddi, Narbeh Derhacobian, Kevin Palatnik and Hoshi Printer.

Our Corporate Governance Guidelines require that a majority of our directors meet the criteria for independence set forth under applicable securities laws, including applicable rules and regulations of the SEC and applicable listing standards of the Nasdaq Stock Market (“Nasdaq”). The Nasdaq listing standards provide that an independent director is one who the Board affirmatively determines is free of any relationship that would interfere with that individual’s exercise of independent judgment. Our Board has reviewed the relationships between the Company, including our subsidiaries and affiliates, and each Board member and Board nominee. Based on its review, the Board has affirmatively determined that Messrs. Auker, Chittipeddi, Derhacobian, Palatnik and Printer currently have no relationships that would interfere with their exercise of independent judgment and that each of them is “independent” in accordance with applicable listing standards of Nasdaq. In addition, the Board has affirmatively determined that Jason Lamb currently has no relationships that would interfere with his exercise of independent judgment and will be “independent” in accordance with applicable listing standards of Nasdaq if elected at the Annual Meeting.

Our Corporate Governance Guidelines provide that the Board will appoint a Chairman of the Board with the approval of a majority of the directors then in office or as otherwise provided in our Bylaws. While any director (including the Chief Executive Officer or other management director) is eligible for appointment as the Chairman of the Board, the Board’s current preferred governance structure is to have an independent director serve as Chairman of the Board. If, however, the positions of Chairman of the Board and Chief Executive Officer are held by the same person, our Corporate Governance Guidelines provide that one of our independent directors will be designated by a majority of the independent directors to serve as our Lead Independent Director. The Board is currently led by Mr. Printer, our independent Chairman of the Board, a position separate from our Chief Executive Officer and President. The Board intends to designate a new Chairman of the Board immediately following the Annual Meeting. Separating the positions of Chief Executive Officer and Chairman of the Board allows our Chief Executive Officer to focus on our day-to-day business, while allowing the Chairman of the Board to lead the Board in its fundamental role of providing advice to and independent oversight of management.

While our management has primary responsibility for identifying and mitigating risks, the Board has overall responsibility for oversight of such risks, with a focus on the most significant risks facing the Company. At least annually, management and the Board jointly review our strategic goals and associated risks. Throughout the year, the Board and the committees to which the Board has delegated responsibility dedicate a portion of their meetings to review and discuss specific risk topics in greater detail.

The Board has delegated responsibility for the oversight of specific risks to Board committees as follows:

The Board’s risk oversight process builds upon management’s enterprise-wide risk assessment and mitigation processes, which include ongoing monitoring of various material short-, intermediate- and long-term risks including those associated with long-term strategy and business operations, regulatory and legal compliance and financial reporting.

Our Board believes that the processes it has established to administer the Board’s risk oversight function would be effective under a variety of leadership frameworks and therefore do not have a material effect on our leadership structure described under “Board Leadership Structure” above.

During fiscal 2026, the Board held 14 board meetings and a total of 12 committee meetings. Each director attended 100% of the meetings of the Board held during the period of his tenure in fiscal 2026.

Although the Chief Executive Officer and other members of senior management are invited to attend meetings of the Board, the members of the Board meet in executive sessions, without executive management present, in conjunction with each of the regularly scheduled meetings of the Board and in special meetings at the discretion of the Board members. Each committee of the Board also has discretion to meet in executive sessions without executive management present in regularly scheduled meetings and in special meetings. In addition, the Audit Committee meets quarterly in separate executive sessions with our independent registered public accounting firm and with our Chief Financial Officer.

Under our Corporate Governance Guidelines, our directors are expected to attend our annual meetings of stockholders. All of our then-current directors attended the 2025 Annual Meeting of Stockholders, held on November 4, 2025.

To facilitate independent director review and to make the most effective use of our directors’ time and capabilities, the Board has established the following standing committees: the Audit Committee, the Compensation Committee and the Corporate Governance and Nominating Committee. The responsibilities of each committee are set forth in a written charter, each of which has been approved by the Board. Each standing committee reviews and assesses the adequacy of its charter on an annual basis. Each such charter is available under the “Investors – Board of Directors – Committee Charters” section of our website at www.lantronix.com. The Board is permitted to establish other committees from time to time as it deems appropriate.

Current committee membership and the number of meetings of each committee in fiscal 2026 are shown in the table below. Mr. Awsare is not a member of any committee. Each of the current directors attended 100% of the meetings held by each committee of the Board on which he served during the period of his tenure in fiscal 2026.

The Audit Committee is composed of three directors, each of whom is independent in accordance with applicable rules of Nasdaq and meets the Nasdaq financial literacy requirements for audit committee service. In addition, the Board has determined that each member of the Audit Committee meets the enhanced independence requirements under the Exchange Act and that Mr. Printer is an “audit committee financial expert” as defined under the rules of the SEC.

The Audit Committee assists the Board in fulfilling its responsibilities for general oversight of the integrity of our financial statements, compliance with legal and regulatory requirements, the qualifications and independence of our independent registered public accounting firm, the performance of our independent registered public accounting firm, risk assessment and risk management, cybersecurity, and finance and accounting functions. The Audit Committee also appoints, retains, terminates, determines compensation for, and oversees our independent registered public accounting firm, reviews the scope of the audit by our independent registered public accounting firm, and reviews the effectiveness of our accounting and internal control functions. The Audit Committee has the authority to obtain advice and assistance from, and receive appropriate funding for, internal or external legal, accounting or other advisers as the Audit Committee deems necessary to carry out its duties.

In addition, the Audit Committee assists the Board in overseeing the implementation and monitoring of the effectiveness of our Code of Business Conduct and Ethics Policy (“Code of Conduct”). The Audit Committee also reviews, with our management and our independent registered public accounting firm, our policies and procedures with respect to risk assessment and risk management relating to financial statements and financial reporting, as well as cybersecurity, investment, capital structure and compliance risk, and the guidelines, policies and processes for monitoring and mitigating those risks. The Audit Committee is also responsible for the review and approval of related party transactions. The Audit Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate.

The Compensation Committee is composed of three directors, each of whom is independent as the term is defined within the Nasdaq listing standards for compensation committee service. The Board has determined that each of the members of the Compensation Committee meets the enhanced independence requirements of Nasdaq and is a “non-employee director” as that term is defined under Rule 16b-3 of the Exchange Act.

The Compensation Committee determines our overall policies on compensation and the compensation of our Chief Executive Officer and other executive officers. In addition, the Compensation Committee administers our equity incentive plans and reviews the philosophy and policies behind, and any material risks created by, the salary, bonus and equity compensation arrangements for all employees. The Compensation Committee also makes recommendations to the Board with respect to amendments to our equity incentive plans. The Compensation Committee also reviews and recommends to the Board the compensation of directors. The Compensation Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate.

The Compensation Committee has the authority to obtain advice and assistance from, and receive appropriate funding for, internal or external legal, compensation, accounting or other advisers as the Compensation Committee deems necessary to carry out its duties. For fiscal 2026, the Compensation Committee retained Compensation

Strategies, Inc. (“Compensation Strategies”) to assist in a review of our executive compensation program, our non-employee director compensation program, and the executive and non-employee director compensation practices at a peer group of companies. As described further under “Executive Compensation - Independent Compensation Consultants” below, the Compensation Committee has assessed the independence of Compensation Strategies and has concluded that its engagement of Compensation Strategies does not raise any conflict of interest with the Company or any of its directors or executive officers. No other compensation consultants were retained for fiscal 2026.

The Corporate Governance and Nominating Committee is composed of three directors, each of whom is independent as the term is defined within the Nasdaq listing standards.

The Corporate Governance and Nominating Committee makes recommendations to the Board regarding candidates for election as directors and is otherwise responsible for matters relating to the nomination of directors, including evaluating the “independence” of directors and director nominees against the independence requirements of the Nasdaq listing standards, SEC rules and other applicable laws. The Corporate Governance and Nominating Committee assists with the structure and membership of Board committees.

The Corporate Governance and Nominating Committee reviews our corporate governance policies and procedures and recommends to the Board changes it deems appropriate. The Corporate Governance and Nominating Committee also oversees the annual Board and committee self-assessment and director performance evaluation process. The Corporate Governance and Nominating Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate.

The Board believes that it should be composed of directors with complementary backgrounds and that directors should, at a minimum, exhibit proven leadership capabilities and experience at a high level of responsibility within their respective fields and have the ability to quickly grasp complex principles of business, finance and technology. Directors should possess the highest personal and professional ethics, integrity and values and should be committed to representing the long-term interests of our stockholders.

When considering a candidate for director, the Corporate Governance and Nominating Committee takes into account a number of factors, including the following:

The Board is primarily focused on evaluating a nominee’s expected contribution to the skills, background, experiences and perspectives, given the then-existing composition of the Board as a whole. In considering the overall composition of the Board, the Board places importance on having directors with executive-level experience in technology companies.

When seeking candidates for director, the Corporate Governance and Nominating Committee may solicit suggestions from incumbent directors, management, stockholders and others. Additionally, the Corporate Governance and Nominating Committee may use the services of a third-party search firm to assist in the identification and review of appropriate candidates. After conducting an initial evaluation of a prospective candidate, the Corporate Governance and Nominating Committee will interview that candidate if it believes the candidate might be suitable. The Corporate Governance and Nominating Committee may also ask the candidate to meet with other members of the Board and with management. If the Corporate Governance and Nominating Committee believes a candidate would be a valuable addition to the Board, it may recommend to the Board that candidate’s appointment or election. The Corporate

Governance and Nominating Committee applies the same standards of review to all prospective candidates for director, regardless of who brings them to the Corporate Governance and Nominating Committee’s attention.

While we do not limit the number of public company boards on which our directors are permitted to serve, our Corporate Governance Guidelines require that directors be willing to devote sufficient time to carrying out their duties and responsibilities effectively and should be committed to serve on the Board for an extended period of time. All directors are required to advise the Chairman of the Board, or the Lead Independent Director, if applicable, in advance of accepting an invitation to serve on the Board of another public company and are expected not to accept the invitation if it would materially interfere with the director’s responsibilities as a member of the Board.

We have adopted a Code of Conduct that applies to all of our directors, officers and employees. The Code of Conduct helps our directors, officers and employees understand and adhere to the high ethical standards expected by the Company. The Code of Conduct is posted under the “Investors – Corporate Governance” section of our website at www.lantronix.com. To the extent required by SEC and Nasdaq rules, we intend to promptly disclose future amendments to certain provisions of the code, or waivers of such provisions granted to executive officers and directors on our website at www.lantronix.com.

Concerns relating to accounting, internal controls or auditing matters are brought to the attention of the Chair of the Audit Committee and handled in accordance with procedures established by the Audit Committee with respect to such matters.

As described in the Code of Conduct, we also maintain a whistleblower phone hotline to permit the reporting of violations or suspected violations of the Code of Conduct, anonymously if desired, to our legal department or Audit Committee, as appropriate.

We have adopted an Insider Trading Policy governing the purchase, sale, and other dispositions of our securities by our directors, officers and employees, as well as by the Company. We believe our insider trading policies and procedures are reasonably designed to promote compliance with insider trading laws, rules, and regulations and applicable listing standards. Among other things, our Insider Trading Policy prohibits directors, officers, and other employees from engaging in any transaction in which they may profit from short-term speculative swings in the value of our securities. This includes purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s securities. To limit the likelihood of trading at times when there is a significant risk of insider trading exposure, we have instituted quarterly trading blackout periods and may establish additional trading blackout periods as needed. Our Insider Trading Policy is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

There are no legal proceedings related to any of our directors or executive officers which must be disclosed pursuant to applicable SEC regulations.

Our Board provides a process for stockholders and other interested parties to communicate with our Board or any individual Board member. Stockholders who wish to communicate with the Board can write to the Company’s Corporate Secretary at Lantronix, Inc., 48 Discovery, Suite 250, Irvine, California 92618 or by email at secretary@lantronix.com.

Communications will be distributed to the Board, or to individual directors as appropriate, depending on the facts and circumstances outlined in the communication. The Board has instructed the Corporate Secretary to review all correspondence and to determine, in his or her discretion, whether matters submitted are appropriate for Board consideration. In particular, the Board has directed that communications, such as product or commercial inquiries or

complaints, resumes and other job inquiries, surveys and general business solicitations or advertisements, should not be forwarded to the Board. In addition, material that is unduly hostile, threatening, illegal, patently offensive or similarly inappropriate or unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any director upon request.

Directors who are also employees of the Company are not paid any fees or remuneration for their service on the Board or on any Board committee. In fiscal 2026, we provided the annual compensation described below to directors who are not employees of the Company or any of our subsidiaries (“non-employee directors”). Mr. Awsare, our Chief Executive Officer, was the only director who was also an employee of the Company.

Under our Non-Employee Director Compensation Policy, each non-employee director is entitled to receive the following cash compensation for board services, as applicable:

Under the Non-Employee Director Compensation Policy, directors are not paid fees for service as members on any of our standing committees, apart from the Chair fees discussed above. Further, directors are not paid meeting fees, except that (1) each non-employee director will be paid a meeting fee of $1,000 for each Board meeting attended in person or by telephone in excess of 12 meetings during the fiscal year; and (2) each non-employee director will be paid a meeting fee of $1,000 for attending in person or by telephone each meeting of a standing committee of which he or she is a member in excess of 12 meetings per committee during the fiscal year.

Under our Non-Employee Director Compensation Policy, each of the non-employee directors elected at our annual meeting of stockholders each year has received an award of restricted stock units (“RSUs”), with the number of RSUs for each grant to be determined by dividing $75,000 by the average of the closing prices of a share of our common stock for the last 30 trading days of the fiscal quarter preceding the fiscal quarter in which the grant is made, rounded to the nearest whole share. Each such RSU award is scheduled to vest 50% six months after the grant date and the remaining 50% on the earlier of the first anniversary of the grant date and the day immediately preceding the next annual meeting of stockholders.

If a non-employee director is appointed to the Board other than at the time of an annual meeting of stockholders, the director will receive an initial award of RSUs with a value as of the grant date of $75,000, applying the methodology described above and pro-rated based on the period of the director’s service on the Board during the one-year period following the last annual meeting. This initial award will be scheduled to vest in two installments on the same vesting dates as the annual awards granted to non-employee directors at the last annual meeting (with the RSUs subject to the award allocated proportionately between the two vesting dates based on the director’s period of service on the Board), or if the initial award is granted more than six months after the last annual meeting, the award will be scheduled to vest in one installment on the earlier of the first anniversary of the date of the last annual meeting and the day immediately preceding the next annual meeting.

If a change in control of the Company occurs, all annual and initial grants of RSUs to non-employee directors that are then outstanding will vest in full upon (or immediately prior to) the closing of the transaction.

The Board, upon recommendation of the Compensation Committee, may change the terms of our director compensation program from time to time.

Under the Non-Employee Director Compensation Policy, non-employee directors will be reimbursed for reasonable out of pocket expenses, including travel expenses incurred to attend meetings, up to a maximum of $3,000 per meeting requiring travel.

The table below sets forth the compensation earned by our non-employee directors during fiscal 2026. The compensation paid to Mr. Awsare, who was employed by us and served on the Board during fiscal 2026, is presented below in the Summary Compensation Table and the related explanatory tables. Directors who are also officers or employees of the Company or its subsidiaries receive no additional compensation for their services as directors.

The following table shows the total number of RSUs outstanding, and total number of shares of our common stock subject to outstanding stock options, as of June 30, 2026 for each person who served as a non-employee director during fiscal 2026:

The Compensation Committee, working with its independent compensation consultant, regularly reviews the Company’s non-employee director compensation against the Company’s peers. Following this review in August 2026, the Compensation Committee recommended, and the Board approved, the following compensation structure for non-employee directors to more closely align non-employee director compensation with the compensation provided to board members of the Company’s peer companies:

The Board encourages its members to acquire and hold stock in the Company to link the interests of the directors to the stockholders. The Board has adopted stock ownership guidelines for the non-employee directors of the Company. Under the guidelines, our non-employee directors are each expected to own shares of our common stock with a value equal to three times the annual cash retainer for such director. Progress toward the achievement of these ownership guidelines is based on shares purchased in the open market, or acquired through option exercises or vesting of RSUs. The value of the shareholdings is based on the greater of (1) the closing price of a share of our common stock as of the most recent fiscal year end, or (2) the acquisition value of the shares, determined based upon the purchase price for open market purchases and the fair market value of shares on the date of issuance in the case of shares issued upon the exercise of stock options or settlement of RSUs. The guidelines provide that non-employee directors are expected to establish the minimum ownership levels within five years of adoption of the guidelines or within five years of appointment as a new non-employee director of the Company. Neither the Board nor the Compensation Committee has established stock ownership guidelines for members of the Board who are employees of the Company. All of our current non-employee directors either satisfy the applicable level of share ownership under the guidelines or are within the five-year compliance period.

Our Board currently consists of six directors: James Auker, Saleel Awsare, Sailesh Chittipeddi, Narbeh Derhacobian, Kevin Palatnik and Hoshi Printer. Messrs. Printer and Auker are not standing for re-election.

In connection with its annual review of Board composition, the Corporate Governance and Nominating Committee considers a variety of factors, including the qualifications, experience and contributions of individual directors, the skills and experience represented on the Board as a whole, and feedback received from stockholders. Following the 2025 Annual Meeting of Stockholders, the Company sought feedback from certain of its significant stockholders regarding the voting results for the election of directors. The Committee considered the feedback received, together with other factors relevant to Board composition, in determining the director nominees presented for election at the Annual Meeting.

The Corporate Governance and Nominating Committee has recommended to the Board, and the Board has approved, the nomination of the following five nominees for election as directors at the Annual Meeting, each to serve a one-year term until the 2027 Annual Meeting of Stockholders and until the director’s successor has been duly elected and qualified, or until the director’s earlier resignation or removal: Saleel Awsare, Sailesh Chittipeddi, Narbeh Derhacobian, Jason Lamb and Kevin Palatnik. Mr. Lamb was initially identified as a potential director nominee by members of the Corporate Governance and Nominating Committee, which was followed up with interviews of Mr. Lamb by members of the Corporate Governance and Nominating Committee and Mr. Awsare. The Corporate Governance and Nominating Committee met to discuss his qualifications and recommended Mr. Lamb to the Board as a director nominee for election at the Annual Meeting. The Board, in turn, discussed and unanimously approved the Corporate Governance and Nominating Committee’s recommendation.

Other than Mr. Lamb, each of the nominees presently serves as a director and has served continuously as a director since the date indicated in the nominee’s biography below. All nominees have consented to be named and have indicated their intent to serve if elected. We have no reason to believe any of the nominees will be unable or unwilling for good cause to serve if elected. If any nominee should become unable for any reason or unwilling for good cause to serve, the proxy holders will vote the proxies received by them for another person nominated as a substitute by the Board, or the Board may reduce the number of directors on the Board.

The following table sets forth certain information, in each case as of September 8, 2026, concerning the nominees for director:

The following is a description of the business experience, qualifications, skills and educational background of each of the director nominees, including each nominee’s relevant business experience:

President, Chief Executive Officer & Director

Mr. Awsare has served as a member of our Board and President and Chief Executive Officer since November 2023. Mr. Awsare served as Senior Vice President and General Manager of the Enterprise and Mobile Division of Synaptics Incorporated (“Synaptics”), a developer of human interface hardware and software, from September to November 2023. Prior to that, Mr. Awsare served as Senior Vice President and General Manager of the PC and Peripherals Unit of Synaptics from August 2020 to September 2023; Senior Vice President and General Manager of Synaptics’s IoT Division from April 2019 to July 2020; and Senior Vice President of Corporate Marketing & Investor

Relations at Synaptics from October 2018 until April 2019. Prior to joining Synaptics as Corporate Vice President and General Manager of Audio & Imaging Products in August 2017, Mr. Awsare was President of Conexant Systems, LLC, a software developer and fabless semiconductor company, from March 2016 until Conexant’s acquisition by Synaptics in August 2017, and Conexant’s Senior Vice President & General Manager of Audio & Imaging from April 2012 to March 2016. Prior to joining Conexant, Mr. Awsare served as President of U.S. Operations and General Manager of Audio & Voice Solutions of Nuvoton Technology Corporation, a Taiwan-based semiconductor company, from December 2008 to March 2012.

Mr. Awsare brings a comprehensive knowledge of the enterprise, mobile and IoT markets and a demonstrated record of driving growth and profitability while serving in various management roles in technology companies.

Independent Director

Dr. Chittipeddi has served as a member of our Board since May 2025. Since March 2025, Dr. Chittipeddi has served as a Venture Partner at Novo Tellus Capital Partners, a private equity firm focused on investments in industrial and technology companies in Southeast Asia, and a member of the Board of Directors of Tessolve, a global semiconductor and system-on-chip solutions company. Dr. Chittipeddi previously held various senior roles at Renesas Electronics, a semiconductor manufacturer, including Executive Vice President of Global Operations from October 2023 to March 2025, President of Renesas Electronics America from March 2019 to January 2025, and Executive Vice President and General Manager, IoT and Infrastructure Business Unit from March 2019 to January 2024. Dr. Chittipeddi served as Executive Vice President and Chief Technology Officer, Global Operations at Integrated Device Technology (Nasdaq: IDTI), a supplier of analog mixed-signal products, from March 2014 to March 2019, when it was acquired by Renesas. Previously, Dr. Chittipeddi held various senior management roles at Conexant Systems Inc., a software developer and fabless semiconductor company, including serving as President from July 2009 to April 2011, and managing Global Operations from July 2006 to April 2011. Dr. Chittipeddi’s prior experience includes serving as member of the Board of Directors at Sequans Communications from June 2022 to March 2024, Tessolve from March 2019 to December 2023, and Avalanche Technology, Inc. from March 2019 to December 2021.

Dr. Chittipeddi brings over two decades of executive management experience with public and private technology companies, including extensive experience in managing and scaling global operations, leading mergers, acquisitions and financial restructuring efforts, and advancing the development of innovative technologies.

Independent Director

Mr. Derhacobian has served as a member of our Board since November 2024. Mr. Derhacobian has served as Chief Executive Officer and a director of GuRu Wireless, a developer of advanced multi-watt, over-the-air, wireless power transfer solutions, since April 2022. Previously, Mr. Derhacobian was President and Chief Executive Officer of Parabellum Acquisition Corp. (NYSE: PRBM), a special purpose acquisition company, from February 2021 to December 2023. He was a co-founder of Adesto Technologies (Nasdaq: IOTS), a provider of application specific semiconductors and embedded systems for IoT edge deployments and served as its President and Chief Executive Officer and as a director from January 2006 until its acquisition by Dialog Semiconductor PLC in July 2020. Mr. Derhacobian’s prior experience also includes senior management roles at Advanced Micro Devices, Inc. (Nasdaq: AMD), a multinational semiconductor company, from 1995 to 2000, where he served as engineering manager; Virage Logic Corporation (Nasdaq: VIRL), a provider of semiconductor intellectual property, from 2000 to 2004 where he served as director of engineering; Cswitch from 2004 to 2006 where he served as director of technology development; and Silicon Storage Technology, Inc. (Nasdaq: SSTI) from 1994 to 1995 where he served as senior engineer.

Mr. Derhacobian previously served as director Kinara.ai, a venture backed company focused on high efficiency edge AI processors used in smart edge devices and gateways, from 2022 to 2025, and at Nanosys, a nanotechnology company that develops and manufactures quantum dot materials for display products, from 2021 to 2023.

Mr. Derhacobian brings over two decades of experience as a founder, director and chief executive officer in leading-edge technology companies, as well as extensive mergers and acquisitions experience with both public and private companies and significant operational experience in complex organizations serving Fortune 100 customers.

Director Nominee

Mr. Lamb has served as Chief Executive Officer of The LGL Group, Inc., a holding company engaged in services, merchant investment and manufacturing business activities, since January 2026. He has served as an independent director of Alpha G Investment Management Inc. (formerly Teton Advisors, Inc.) (OTC: TETAA), a holding company providing investment advisory services to open-end funds and separate account clients, since September 2021, and Morgan Group Holding Co. (OTC: MGHL), a holding company seeking acquisitions as part of its strategic alternatives, since March 2026. Previously, Mr. Lamb served as Chief Strategy Officer of Blacksea Technologies, a manufacturer of unmanned surface and subsea vessels, from July 2022 until its acquisition by AEVEX Aerospace in December 2025. Mr. Lamb was a founder and Managing Partner of Hard Yards, a product development and consultancy company, from July 2016 until its acquisition by Blacksea Technologies. Prior to his private sector career, Mr. Lamb served as an officer in the United States Navy SEALs teams. Mr. Lamb holds a Master of Business Administration from the University of Virginia Darden School of Business, a Master of Science in the Management of Information Technology from the University of Virginia, a Master of Arts in National Security and Strategic Studies from the U.S. Naval War College, and a Bachelor of Science in Political Science from the United States Naval Academy.

Mr. Lamb brings more than 30 years of leadership experience across defense, intelligence, advanced technology development, and capital markets, including executive management roles such as chief executive officer and chief strategy officer

Independent Director

Mr. Palatnik has served as a member of our Board since November 2024. Mr. Palatnik served as Executive Vice President and Chief Financial Officer of Coherent, Inc. (Nasdaq: COHR), an optical materials and semiconductor company, from February 2016 until its acquisition by II-VI Incorporated in July 2022. Prior to that, Mr. Palatnik served as the Chief Financial Officer of Audience, Inc., a provider of intelligent voice and audio solutions for mobile devices, from August 2011 until Audience’s acquisition by Knowles Corporation (NYSE: KN) in July 2015. From April 2006 to November 2010, Mr. Palatnik held various roles at Cadence Design Systems, Inc. (Nasdaq: CDNS), an electronic design automation software company, including as its Senior Vice President and Chief Financial Officer. Mr. Palatnik served as a member of the board of directors and chair of the audit committee of Adesto (Nasdaq: IOTS) from September 2015 to July 2020, and as a director and chair of the audit committee of Parabellum Acquisition Corp. (NYSE: PRBM) from September 2021 until December 2023.

Mr. Palatnik brings over two decades of senior financial management experience in leading-edge technology companies, including roles as chief financial officer and audit committee member.

A director nominee is elected to the Board if he receives the affirmative vote of a majority of the votes cast with respect to his election. In other words, the number of shares voted “FOR” a director nominee must exceed the number of shares voted “AGAINST” that nominee’s election. Abstentions and broker non-votes will not be treated as votes cast and will not be counted in determining the outcome of a director’s election.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE FIVE NOMINEES SET FORTH ABOVE.

The Audit Committee has appointed Baker Tilly US, LLP (“Baker Tilly”) as our independent registered public accounting firm for our fiscal year ending June 30, 2027. Baker Tilly was also our independent registered public accounting firm for fiscal 2026 and fiscal 2025. Representatives of Baker Tilly are expected to attend the Annual Meeting and will be available to respond to appropriate questions and to make a statement if they so desire. Although we are not required to seek stockholder ratification of this appointment, the Board believes that doing so is consistent with good corporate governance practice. If the appointment is not ratified, the Audit Committee will explore the reasons for stockholder rejection and will reconsider the appointment. Even if the appointment is ratified, the Audit Committee, in its sole discretion, may direct the appointment of a different independent registered public accountants any time during the year if the Audit Committee determines that the change would be in our best interests.

The following table presents the aggregate fees billed for each of the last two fiscal years for professional services rendered by Baker Tilly:

Audit Fees. Consist of fees billed for professional services rendered for (i) the audit of our consolidated financial statements and review of our quarterly interim consolidated financial statements, (ii) the audit of the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, and (iii) other services that are normally provided by our independent registered public accountants in connection with statutory and regulatory filings or engagements.

Audit-Related Fees. Consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our consolidated financial statements but are not reported under “Audit Fees.” These fees were related to the audits of our 401(k) employee benefit plan, registration statement consents, and other technical attestation services.

Tax Fees. Consist of fees billed for professional services, including tax advice, tax planning, and preparation of returns relating to federal, state and international taxes.

All Other Fees. There were no fees billed by our independent registered public accountants for other services in fiscal 2026 or fiscal 2025.

The Audit Committee pre-approves all audit and non-audit services performed by our independent registered public accountants in order to ensure that the provision of such services does not impair the auditor’s independence. Our Audit Committee at least annually reviews and provides general pre-approval for the services that may be provided by the independent registered public accounting firm. The term of any general pre-approval is 12 months from the date of pre-approval, unless the Audit Committee specifically provides for a different period. If our Audit Committee has not provided general pre-approval, then the type of service requires specific pre-approval by our Audit Committee. The Audit Committee does not delegate its responsibilities to pre-approve services performed by our independent registered public accountants to management. The Audit Committee may delegate, and has delegated, pre-approval authority to one or more of its members. The member or members to whom such authority is delegated must report any pre-approval decisions to the Audit Committee at its next scheduled meeting.

The annual audit services engagement terms and fees are subject to the specific pre-approval of the Audit Committee. Our Audit Committee pre-approved all audit, audit-related, tax and other services performed by Baker Tilly in fiscal 2025 and in fiscal 2026.

Approval of the non-binding, advisory proposal to ratify the appointment of Baker Tilly as our independent registered public accountants for the fiscal year ending June 30, 2027 requires the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting and entitled to vote thereon. Abstaining has the same effect as voting against this proposal.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF BAKER TILLY US, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING JUNE 30, 2027.

As required by Section 14A of the Exchange Act, at the Annual Meeting, we are providing our stockholders the opportunity to vote on a non-binding, advisory resolution to approve the compensation paid to our named executive officers, which is described in the section titled “Executive Compensation” in this proxy statement. Accordingly, the following resolution will be submitted for a stockholder vote at the Annual Meeting:

Our executive compensation program is designed to provide a competitive level of compensation necessary to align the financial interests of our executives with those of our stockholders, to motivate our executives to achieve short-term and long-term corporate goals that the Compensation Committee believes will enhance stockholder value, and to attract and retain talented and experienced executives. In order to align executive pay with both our performance and our stockholders’ interests, a significant portion of compensation paid to our named executive officers is allocated to performance-based, short- and long-term incentive programs, to make executive pay dependent on our performance (or “at risk”), and in the case of equity awards, with the value also being dependent on changes in our stock price through the time of payment or exercise of the award. In addition, we intend that as an executive officer’s responsibility and ability to affect the financial results of the Company increases, the portion of that executive officer’s total compensation deemed “at risk” should increase.

We urge our stockholders to read the Executive Compensation section of this proxy statement, which more thoroughly discusses how our compensation philosophy is implemented through our compensation policies and procedures. The Compensation Committee and the Board believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving our goals.

We are requesting stockholder approval, on a non-binding, advisory basis, of the compensation paid to our named executive officers as disclosed in this proxy statement, pursuant to the SEC’s compensation disclosure rules. This vote is an advisory vote only and will not be binding on the Company, the Board or the Compensation Committee, and will not be construed as overruling a decision by, or creating or implying any additional fiduciary duty for, the Company, the Board or the Compensation Committee. Although the vote is non-binding, the Board and the Compensation Committee value the opinions of our stockholders and will consider the outcome of the stockholder vote on this proposal when assessing any potential changes to our compensation philosophy and policies.

The Company’s current policy is to provide our stockholders with an advisory vote on the compensation paid to our named executive officers each year at the annual meeting of stockholders. It is expected that the next advisory vote following the Annual Meeting on the compensation paid to our named executive officers will be held at the 2027 Annual Meeting of Stockholders.

The non-binding, advisory approval of the compensation paid to our named executive officers as disclosed in this proxy statement requires the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting and entitled to vote thereon. Abstaining has the same effect as voting against this proposal and broker non-votes will not be counted in determining the outcome of this proposal.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS AN ADVISORY VOTE “FOR” APPROVAL OF THE COMPENSATION PAID TO THE COMPANY’S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.

At the Annual Meeting, stockholders will be asked to approve an amendment to the Lantronix, Inc. 2020 Performance Incentive Plan (the “2020 Plan”), which was adopted, subject to stockholder approval, by the Board of Directors on August 25, 2026. The 2020 Plan currently limits the aggregate number of shares of the Company’s Common Stock that may be delivered pursuant to awards granted under the plan to 7,149,047 shares. The proposed amendment to the 2020 Plan would increase the aggregate number of shares of the Company’s Common Stock available for award grants under the plan by 1,800,000 shares (so that the new aggregate share limit for the 2020 Plan would be 8,949,047 shares).

As of September 8, 2026, a total of 3,190,876 shares of the Company’s Common Stock were then subject to outstanding awards granted under the Company’s equity incentive plans (including 2,483,163 shares that were then subject to outstanding awards under the 2020 Plan), and an additional 80,032 shares of the Company’s Common Stock were then available for new award grants under the 2020 Plan. In addition, as of September 8, 2026, a total of 26,500 shares of the Company’s common stock were then subject to outstanding awards granted under the Company’s Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”), and a total of 681,213 shares of the Company’s common stock were then subject to outstanding awards granted to certain officers and other employees as an inducement to their commencing employment with the Company that are not under the Company’s stock incentive plans (the “Inducement Awards”).

The Company believes that incentives and stock-based awards focus employees on the objective of creating stockholder value and promoting the success of the Company, and that incentive compensation plans like the 2020 Plan are an important attraction, retention and motivation tool for participants in the plan. Our Board of Directors approved the proposed share increase for the 2020 Plan based on a belief that the number of shares currently available for new award grants under the plan does not give the Company sufficient authority and flexibility to adequately provide for future incentives. Our Board of Directors believes that the additional shares that would be available for grant under the 2020 Plan will give us greater flexibility to structure future incentives and better attract, retain and reward our executives and key employees.

As described in more detail below under “Executive Compensation—Equity Awards,” we have updated our equity grant programs with changes designed to more closely align our equity compensation practices with the interests of our stockholders while reducing overall share usage and potential dilution. We continue to include grants of performance-based stock units that vest based solely on total stockholder return over a three-year performance period relative to the companies in the Russell Microcap Index and have increased our use of other performance-based equity awards.

We have also taken steps to reduce our overall use of shares for employee compensation. We have focused equity grants on more senior employees and key engineering talent, reducing the number of employees eligible to receive grants, and have reduced our reliance on inducement grants. In addition, the shares previously reserved for issuance under our Employee Stock Purchase Plan (“ESPP”) have essentially been exhausted (approximately 26,000 shares remaining as of September 8, 2026), and we are not seeking stockholder approval to reserve additional shares for the ESPP at the Annual Meeting. These actions are intended to reduce overall share usage and potential dilution and should be considered together with our request for additional shares under the 2020 Plan.

If stockholders do not approve this 2020 Plan proposal, the Company will continue to have the authority to grant awards under the 2020 Plan as it was previously in effect, without giving effect to the proposed amendment.

The principal terms of the 2020 Plan, including the proposed amendment described above, are summarized below. The following summary is qualified in its entirety by the full text of the 2020 Plan (as proposed to be amended), which appears as Exhibit A to this Proxy Statement.

Purpose. The purpose of the 2020 Plan is to promote the success of the Company by providing an additional means for us to attract, motivate, retain and reward selected employees and other eligible persons through the grant of awards. Equity-based awards are also intended to further align the interests of award recipients and our stockholders.

Administration. Our Board of Directors or one or more committees appointed by our Board of Directors will administer the 2020 Plan. Our Board of Directors has delegated general administrative authority for the 2020 Plan to the Compensation Committee. The Board of Directors or a committee thereof (within its delegated authority) may delegate

different levels of authority to different committees or persons with administrative and grant authority under the 2020 Plan. (The appropriate acting body, be it the Board of Directors or a committee or other person within its delegated authority is referred to in this proposal as the “Administrator”).

The Administrator has broad authority under the 2020 Plan, including, without limitation, the authority:

No Repricing. In no case (except due to an adjustment to reflect a stock split or other event referred to under “Adjustments” below, or any repricing that may be approved by stockholders) will the Administrator (1) amend an outstanding stock option or stock appreciation right to reduce the exercise price or base price of the award, (2) cancel, exchange, or surrender an outstanding stock option or stock appreciation right in exchange for cash or other awards for the purpose of repricing the award, or (3) cancel, exchange, or surrender an outstanding stock option or stock appreciation right in exchange for an option or stock appreciation right with an exercise or base price that is less than the exercise or base price of the original award.

Eligibility. Persons eligible to receive awards under the 2020 Plan include officers or employees of the Company or any of its subsidiaries, directors of the Company, and certain consultants and advisors to the Company or any of its subsidiaries. As of September 8, 2026, approximately 330 officers and employees of the Company and its subsidiaries (including all of the Company’s named executive officers), and each of our five non-employee directors, were considered eligible under the 2020 Plan. In addition, two consultants engaged by the Company and its subsidiaries were then considered eligible under the 2020 Plan.

Aggregate Share Limit. Currently, the maximum number of shares of the Company’s common stock that may be issued or transferred pursuant to awards under the 2020 Plan equals the sum of the following (such total number of shares, the “Share Limit”):

If stockholders approve the proposed amendment to the 2020 Plan, the Share Limit will be increased by 1,800,000 shares.

As of September 8, 2026, 80,032 shares were available for additional award grant purposes under the 2020 Plan, 50,432 shares were subject to stock options then outstanding under the 2020 Plan, and 2,432,731 shares were subject to restricted stock and restricted stock unit awards (including the target number of shares subject to performance-based awards) then outstanding under the 2020 Plan.

Additional Share Limit. The maximum number of shares that may be delivered pursuant to options qualified as incentive stock options granted under the plan is 2,500,000 shares. (For clarity, any shares issued in respect of incentive stock options granted under the 2020 Plan will also count against the overall Share Limit above.)

Share-Limit Counting Rules. The Share Limit of the 2020 Plan is subject to the following rules:

In addition, the 2020 Plan generally provides that shares issued in connection with awards that are granted by or become obligations of the Company through the assumption of awards (or in substitution for awards) in connection with an acquisition of another company will not count against the shares available for issuance under the 2020 Plan. The Company may not increase the applicable share limits of the 2020 Plan by repurchasing shares of common stock on the market (by using cash received through the exercise of stock options or otherwise).

Types of Awards. The 2020 Plan authorizes stock options, stock appreciation rights, and other forms of awards granted or denominated in the Company’s common stock or units of the Company’s common stock, as well as cash bonus awards. The 2020 Plan retains flexibility to offer competitive incentives and to tailor benefits to specific needs and circumstances. Any award may be structured to be paid or settled in cash.

A stock option is the right to purchase shares of the Company’s common stock at a future date at a specified price per share (the “exercise price”). The per share exercise price of an option generally may not be less than the fair market value of a share of the Company’s common stock on the date of grant. The maximum term of an option is ten years from the date of grant. An option may either be an incentive stock option or a nonqualified stock option. Incentive stock option benefits are taxed differently from nonqualified stock options, as described under “Federal Income Tax Consequences of Awards Under the 2020 Plan” below. Incentive stock options are also subject to more restrictive terms and are limited in amount by the U.S. Internal Revenue Code and the 2020 Plan. Incentive stock options may only be granted to employees of the Company or a subsidiary.

A stock appreciation right is the right to receive payment of an amount equal to the excess of the fair market value of share of the Company’s common stock on the date of exercise of the stock appreciation right over the base price of the stock appreciation right. The base price will be established by the Administrator at the time of grant of the stock appreciation right and generally may not be less than the fair market value of a share of the Company’s common stock on the date of grant. Stock appreciation rights may be granted in connection with other awards or independently. The maximum term of a stock appreciation right is ten years from the date of grant.

The other types of awards that may be granted under the 2020 Plan include, without limitation, stock bonuses, restricted stock, performance stock, stock units or phantom stock (which are contractual rights to receive shares of stock, or cash based on the fair market value of a share of stock), dividend equivalents which represent the right to receive a payment based on the dividends paid on a share of stock over a stated period of time, or similar rights to purchase or acquire shares, and cash awards.

Any awards under the 2020 Plan (including awards of stock options and stock appreciation rights) may be fully-vested at grant or may be subject to time- and/or performance-based vesting requirements.

Dividend Equivalents; Deferrals. The Administrator may provide for the deferred payment of awards, and may determine the other terms applicable to deferrals. The Administrator may provide that awards under the 2020 Plan (other than options or stock appreciation rights), and/or deferrals, earn dividends or dividend equivalents based on the amount of dividends paid on outstanding shares of Common Stock, provided that any dividends and/or dividend equivalents as to the portion of an award that is subject to unsatisfied vesting requirements will be subject to termination and forfeiture to the same extent as the corresponding portion of the award to which they relate in the event the applicable vesting requirements are not satisfied (or, in the case of a restricted stock or similar award where the dividend must be paid as a matter of law, the dividend payment will be subject to forfeiture or repayment, as the case may be, if the related vesting conditions are not satisfied).

Assumption and Termination of Awards. If an event occurs in which the Company does not survive (or does not survive as a public company in respect of its common stock), including, without limitation, a dissolution, merger, combination, consolidation, conversion, exchange of securities, or other reorganization, or a sale of all or substantially all of the business, stock or assets of the Company, awards then-outstanding under the 2020 Plan will not automatically become fully vested pursuant to the provisions of the 2020 Plan so long as such awards are assumed, substituted for or otherwise continued. However, if awards then-outstanding under the 2020 Plan are to be terminated in such circumstances (without being assumed or substituted for), such awards would generally become fully vested (with any

performance goals applicable to the award being deemed met at the “target” performance level), subject to any exceptions that the Administrator may provide for in an applicable award agreement. The Administrator also has the discretion to establish other change in control provisions with respect to awards granted under the 2020 Plan. For example, the Administrator could provide for the acceleration of vesting or payment of an award in connection with a corporate event or in connection with a termination of the award holder’s employment. For the treatment of outstanding equity awards held by the named executive officers in connection with a termination of employment and/or a change in control of the Company, please see the “Severance and Change in Control Arrangements with Named Executive Officers” section below in this Proxy Statement.

Transfer Restrictions. Subject to certain exceptions contained in Section 5.6 of the 2020 Plan, awards under the 2020 Plan generally are not transferable by the recipient other than by will or the laws of descent and distribution and are generally exercisable, during the recipient’s lifetime, only by the recipient. Any amounts payable or shares issuable pursuant to an award generally will be paid only to the recipient or the recipient’s beneficiary or representative. The Administrator has discretion, however, to establish written conditions and procedures for the transfer of awards to other persons or entities, provided that such transfers comply with applicable federal and state securities laws and are not made for value (other than nominal consideration, settlement of marital property rights, or for interests in an entity in which more than 50% of the voting securities are held by the award recipient or by the recipient’s family members).

Adjustments. As is customary in incentive plans of this nature, each share limit and the number and kind of shares available under the 2020 Plan and any outstanding awards, as well as the exercise or purchase prices of awards, and performance targets under certain types of performance-based awards, are subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the stockholders.

No Limit on Other Authority. The 2020 Plan does not limit the authority of the Board of Directors or any committee to grant awards or authorize any other compensation, with or without reference to the Company’s common stock, under any other plan or authority.

Termination of or Changes to the 2020 Plan. The Board of Directors may amend or terminate the 2020 Plan at any time and in any manner. Stockholder approval for an amendment will be required only to the extent then required by applicable law or deemed necessary or advisable by the Board of Directors. Unless terminated earlier by the Board of Directors and subject to any extension that may be approved by stockholders, the authority to grant new awards under the 2020 Plan will terminate on August 30, 2030. Outstanding awards, as well as the Administrator’s authority with respect thereto, generally will continue following the expiration or termination of the plan. Generally speaking, outstanding awards may be amended by the Administrator (except for a repricing), but the consent of the award holder is required if the amendment (or any plan amendment) materially and adversely affects the holder.

The U.S. federal income tax consequences of the 2020 Plan under current federal law, which is subject to change, are summarized in the following discussion of the general tax principles applicable to the 2020 Plan. This summary is not intended to be exhaustive and, among other considerations, does not describe the deferred compensation provisions of Section 409A of the U.S. Internal Revenue Code to the extent an award is subject to and does not satisfy those rules, nor does it describe state, local, or international tax consequences.

With respect to nonqualified stock options, the company is generally entitled to deduct and the participant recognizes taxable income in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. With respect to incentive stock options, the company is generally not entitled to a deduction nor does the participant recognize income at the time of exercise, although the participant may be subject to the U.S. federal alternative minimum tax.

The current federal income tax consequences of other awards authorized under the 2020 Plan generally follow certain basic patterns: nontransferable restricted stock subject to a substantial risk of forfeiture results in income recognition equal to the excess of the fair market value over the price paid (if any) only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant); bonuses, stock appreciation rights, cash and stock-based performance awards, dividend equivalents, stock units, and other types of awards are generally subject to tax at the time of payment; and compensation otherwise effectively deferred is taxed when paid. In each of the foregoing cases, the company will generally have a corresponding deduction at the time the participant recognizes income.

If an award is accelerated under the 2020 Plan in connection with a “change in control” (as this term is used under the U.S. Internal Revenue Code), the company may not be permitted to deduct the portion of the compensation attributable to the acceleration (“parachute payments”) if it exceeds certain threshold limits under the U.S. Internal Revenue Code (and certain related excise taxes may be triggered). Furthermore, under Section 162(m) of the Code, the aggregate compensation in excess of $1,000,000 payable to current or former Named Executive Officers (including amounts attributable to equity-based and other incentive awards) may not be deductible by the Company in certain circumstances.

The Company has not approved any awards that are conditioned upon stockholder approval of this 2020 Plan proposal. As of September 8, 2026, 80,032 shares remain available for future awards under the 2020 Plan. Except for the annual equity awards to our non-employee directors described in the following paragraph, the number and terms of future awards under the 2020 Plan are not currently determinable because such awards will be limited by the existing share reserve. If the proposed amendment to the 2020 Plan had been in effect in fiscal 2026, the Company expects that its award grants for fiscal 2026 would not have been substantially different from those actually made in that year under the 2020 Plan. For information regarding stock-based awards granted to the Company’s named executive officers during fiscal 2026, see the material under the heading “Executive Compensation” below.

As described under “Compensation of Non-Employee Directors” above, our Non-Employee Director Compensation Policy provides for each non-employee director to receive an award of restricted stock units at our annual meeting of stockholders, with the number of shares subject to the award determined by dividing $90,000 by the average of the closing prices of a share of our common stock for the last 30 trading days of the fiscal quarter preceding the fiscal quarter in which the grant is made. Assuming, for illustrative purposes only, that the price of our common stock used for the conversion of the dollar amount set forth above into shares is $5.27 (the closing price of our common stock on September 8, 2026), the number of shares that would be allocated to four non-employee directors as a group pursuant to the annual grant formula would be 68,308 shares in calendar 2026 (resulting in a 11,724 share reserve available for future awards) and an aggregate of 273,232 shares through 2029 (the four annual meetings dates remaining in the term of the 2020 Plan) based on the assumed price. This calculation assumes that there are no new eligible directors, there will continue to be four eligible directors seated and there are no changes to the awards granted under the director equity grant program or the timing of such awards.

The following paragraphs include additional information to help you assess the potential dilutive impact of the Company’s equity awards and the 2020 Plan. In addition to awards granted under the 2010 Plan and the Inducement Awards noted above, the Company also maintains the 2013 Employee Stock Purchase Plan (the “ESPP”). The ESPP generally provides for broad-based participation by employees of the Company (and certain of its subsidiaries) and affords employees who elect to participate an opportunity to purchase shares of the Company’s common stock at a discount. The share reserve under the ESPP has essentially been exhausted (approximately 26,000 shares remaining), and the Company is not seeking stockholder approval to authorize additional shares for issuance under the ESPP at the Annual Meeting. Certain information regarding the number of shares of Company common stock available for issuance under the ESPP is included under the heading “Equity Compensation Plan Information” below. The discussion that follows in this “Specific Benefits” section does not include any shares that have been purchased under, may be purchased in the current purchase period under, or that remain available for issuance or delivery under the ESPP.

“Overhang” refers to the number of shares of the Company’s common stock that are subject to outstanding awards or remain available for new award grants. The following table shows the total number of shares of the Company’s common stock that were subject to outstanding restricted stock and restricted stock unit awards granted under the 2020 Plan, that were subject to outstanding stock options granted under the 2020 Plan, and that were then available for new award grants under the 2020 Plan as of June 30, 2026 and as of September 8, 2026. (In this 2020 Plan proposal, the number of shares of the Company’s common stock subject to restricted stock and restricted stock unit awards granted during any particular period or outstanding on any particular date is presented based on the actual number of shares of the Company’s common stock covered by those awards. For awards subject to performance-based vesting requirements, the number of shares presented is based on the target level of performance.)

As of June 30, 2026, our fiscal year end, a total of 3,097,596 shares of the Company’s common stock were subject to all outstanding awards granted under the Company’s equity compensation plans (including the shares then subject to outstanding awards under the 2020 Plan, the 2010 Plan and the Inducement Awards, as well as outstanding awards assumed by the Company in connection with acquisitions, but exclusive of shares that employees may purchase under the ESPP), of which 729,600 shares were then subject to outstanding restricted stock and restricted stock unit awards (excluding performance-based vesting awards), 1,291,064 shares were then subject to outstanding performance-based vesting restricted stock and restricted stock unit awards, and 76,932 shares were then subject to outstanding stock options (with such stock options having a weighted-average exercise price of $4.50 and a weighted-average remaining term of 2.6 years as of June 30, 2026). As of September 8, 2026, a total of 3,174,926 shares of the Company’s common stock were subject to all outstanding awards granted under the Company’s equity compensation plans (including the shares then subject to outstanding awards under the 2020 Plan, the 2010 Plan and the Inducement Awards, as well as outstanding awards assumed by the Company in connection with acquisitions, but exclusive of shares that employees may purchase under the ESPP), of which 1,573,232 shares were then subject to outstanding restricted stock and restricted stock unit awards (excluding performance-based vesting awards), 1,524,762 shares were then subject to outstanding performance-based vesting restricted stock and restricted stock unit awards, and 76,932 shares were then subject to outstanding stock options.

As of September 8, 2026, the Company’s total equity award overhang stood at approximately 7.03% of our common stock issued and outstanding. If shareholders approve the 1,800,000 additional shares requested under this Proposal 4, our pro forma total overhang will be approximately 10.87% of our issued and outstanding shares, which the Board believes reflects disciplined management of our grant program and represents a reasonable level of potential dilution for a publicly traded technology company to maintain competitive equity compensation.

The weighted-average number of shares of the Company’s common stock issued and outstanding in each of the last three fiscal years was 37,386,000 shares issued and outstanding in fiscal 2024; 38,613,000 shares issued and outstanding in fiscal 2025; and 40,145,000 shares issued and outstanding in fiscal 2026. The number of shares of the Company’s common stock issued and outstanding as of June 30, 2026 and September 8, 2026 was 46,594,283 and 46,879,400 shares, respectively.

“Burn rate” refers to the number of shares that are subject to awards that we grant over a particular period of time. The Company’s equity-award burn rate has declined from 7.2% in fiscal 2024 to 5.4% in fiscal 2025 and 3.8% in fiscal 2026. Based on the Company’s analysis using applicable Institutional Shareholder Services (“ISS”) methodology, the Company’s fiscal 2026 burn rate was below the applicable threshold for its peer group. The total number of shares of the Company’s common stock subject to awards that the Company granted under the 2020 Plan, the 2010 Plan and the Inducement Awards in each of the last three fiscal years, and to date (as of September 8, 2026) are as follows:

Thus, the total number of shares of the Company’s common stock subject to awards granted under the 2020 Plan, the 2010 Plan and the Inducement Awards per year over the last three fiscal years (fiscal 2024, 2025 and 2026) has been, on average, 3.6% of the weighted-average number of shares of the Company’s common stock issued and outstanding for the corresponding year, and this percentage is consistent with the Company’s fiscal 2027 equity awards through September 8, 2026 (which, as noted above, cover 1.3% of the number of shares of the Company’s common stock issued and outstanding shares on September 8, 2026). Performance-based vesting awards have been included above in the year in which the award was granted. The actual number of performance-based vesting restricted stock and restricted stock unit awards that became eligible to vest each year because the applicable performance-based condition was satisfied in that year (subject to the satisfaction of any applicable time-based vesting requirements) was as follows: 149,083 in fiscal 2024, and 668,992 in fiscal 2025, 0 in fiscal 2026, and 112,000 (as of September 8, 2026) in fiscal 2027.

The total number of shares of our common stock that were subject to awards granted under the 2020 Plan and the 2010 Plan that terminated or expired and thus became available for new award grants under the 2020 Plan, in each of the last three fiscal years, and to date (as of September 8, 2026) in fiscal 2027 are as follows: 189,888 in fiscal 2024, 642,343 in fiscal 2025, 407,372 in fiscal 2026, and 35,728 in fiscal 2027. Shares subject to 2020 Plan and 2010 Plan awards that terminated or expired and became available for new award grants under the 2020 Plan have been included when information is presented in this 2020 Plan proposal on the number of shares available for new award grants under the 2020 Plan.

The Compensation Committee anticipates that the 1,800,000 additional shares requested for the 2020 Plan (together with the shares available for new award grants under the 2020 Plan and assuming usual levels of shares becoming available for new awards as a result of forfeitures of outstanding awards) will provide the Company with flexibility to continue to grant equity awards under the 2020 Plan through approximately the end of fiscal 2029 (reserving sufficient shares to cover potential payment of performance-based awards at maximum payment levels). However, this is only an estimate, in the Company’s judgment, based on current circumstances. The total number of shares that are subject to the Company’s award grants in any one year or from year-to-year may change based on a number of variables, including, without limitation, the value of the Company’s common stock (since higher stock prices generally require that fewer shares be issued to produce awards of the same grant date fair value), changes in

competitors’ compensation practices or changes in compensation practices in the market generally, changes in the number of employees, changes in the number of directors and officers, acquisition activity and the need to grant awards to new employees in connection with acquisitions, the need to attract, retain and incentivize key talent, the type of awards the Company grants, the number of shares that become available for new award grants pursuant to the terms of the plan (for example, as a result of award forfeitures), whether and the extent to which any applicable performance-based vesting requirements are satisfied, and how the Company chooses to balance total compensation between cash and equity-based awards.

The closing market price for a share of the Company’s common stock as of September 8, 2026 was $5.27 per share.

As of September 8, 2026, awards covering 9,004,337 shares of the Company’s Common Stock had been granted under the 2020 Plan. (This number of shares includes all shares subject to awards before giving effect to forfeitures and performance-based awards measured at the targeted level of performance.) The following table shows information regarding the distribution of those awards among the persons and groups identified below, option exercises and restricted stock and restricted stock units vesting prior to and option and unvested restricted stock and restricted stock units holdings as of that date.

For more information on the Company’s equity compensation plans, see the material under the heading “Equity Compensation Plan Information” below.

The approval of the proposed amendment to the 2020 Plan requires the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting and entitled to vote thereon. Abstaining has the same effect as voting against this proposal and broker non-votes will not be counted in determining the outcome of this proposal.

The Board of Directors believes that the proposed amendment to the 2020 Plan will promote the interests of the Company and its stockholders and will help the Company and its subsidiaries continue to be able to attract, retain and reward persons important to our success. We believe the additional shares are necessary to maintain a competitive, performance-oriented equity program through approximately fiscal 2029 (based on the assumptions noted above). The Company has reduced its burn rate as described above. The authorization is intended to support retention and value creation while maintaining disciplined control over dilution.

All members of the Board of Directors and all of the Company’s executive officers are eligible for awards under the 2020 Plan and thus have a personal interest in the approval of this 2020 Plan proposal.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” APPROVAL OF THE AMENDMENT TO THE 2020 PERFORMANCE INCENTIVE PLAN.

The following section describes the material elements of compensation paid to our “named executive officers” and should be read together with the compensation tables and related disclosures set forth below. Our named executive officers include our principal executive officer for the fiscal year and the two other most highly compensated executive officers serving on the last day of the fiscal year. Individuals who served as named executive officers during the fiscal year but are no longer serving as executive officers at the end of the fiscal year may also need to be included as named executive officers in certain circumstances.

For fiscal 2026, our named executive officers were: Saleel Awsare, our President and Chief Executive Officer; Brent Stringham, our Chief Financial Officer; and Mathi Gurusamy, our Chief Product and Strategy Officer.

Our compensation program is designed to drive behavior that aligns executive pay with stockholder interests through pay-for-performance outcomes consistent with the company’s transformation and growth strategy, at levels that allow us to attract and retain high quality talent. Our executive compensation philosophy reflects a combination of rigorous performance goals and short- and long-term incentive opportunities. We engage the services of an independent outside compensation consultant in developing our executive compensation program.

The executive compensation program approved by our Compensation Committee includes the following elements:

The Compensation Committee believes that executive compensation should be based primarily on objectively determinable factors, both for the Company on its own, as well as in comparison to peer companies. The Compensation Committee also believes that executive compensation should have a component based additionally, although not primarily, on subjective factors, such as leadership, how well each executive helps the Company achieve its strategic goals, each executive’s ability to attract, retain and develop key talent, and how each executive’s efforts contribute to enhancing the Company’s relationship and status with the investor community. The use of both objective and subjective factors, however, does not prevent the Compensation Committee from adjusting compensation up or down if, after considering all of the relevant circumstances, it believes total compensation can be structured to better serve our stockholders’ interests.

We also believe that stockholder interests are further served by other executive compensation-related practices that we follow. These practices include:

Our executive compensation program is based on principles designed to:

The Compensation Committee’s decisions on target compensation for specific individuals are also influenced by a variety of factors, including level of responsibility and title, Company and individual performance, peer group data, prior compensation and general business conditions.

Our Compensation Committee was appointed by the Board and consists entirely of directors who our Board has determined are independent directors under the Nasdaq listing standards and “non-employee directors” for purposes of Rule 16b-3 under the Exchange Act.

Our Compensation Committee is responsible for, among other things:

Our Compensation Committee also analyzes the alignment of our overall executive compensation package with our compensation philosophy and objectives.

The Compensation Committee annually determines the compensation levels for our executive officers by considering several factors, including competitive market data, each executive officer’s roles and responsibilities, how the executive officer is performing those responsibilities and our financial performance.

The Compensation Committee makes all decisions for the total direct compensation - that is, base salary, cash incentive awards under our incentive bonus plan, and stock-based awards - of our executive officers and other members of our senior management, including the named executive officers.

At the request of the Compensation Committee, our Chief Executive Officer and other officers may attend meetings of the Compensation Committee or meetings of our Board at which executive compensation is discussed. The Compensation Committee considers the recommendations from our Chief Executive Officer with respect to executive compensation. While our Chief Executive Officer discusses his recommendations with the Compensation Committee, he does not participate in deliberation or determination with respect to his own compensation.

The Compensation Committee may also engage independent compensation consultants to assist the Compensation Committee in its duties, including providing advice regarding industry trends and benchmarking information relating to the form and amount of compensation provided to executives by companies with which we compete for executive talent and other similarly situated companies.

When considering a proposed compensation package for an executive officer, the Compensation Committee considers both the compensation package as a whole and each element of total compensation. For example, before determining officer compensation, the Compensation Committee reviews, for each executive, each element of compensation paid in the prior fiscal year, including base salary, incentive bonus, and the value of equity awards, information regarding equity awards made in prior periods, and competitive market data. The Compensation Committee uses this information to assess the overall effect and long-term implications of compensation decisions, rather than viewing individual decisions in isolation.

At our 2025 Annual Meeting of Stockholders, our stockholders approved, on a non-binding, advisory basis, the compensation paid to our named executive officers described in our 2025 proxy statement. Approximately 93.9% of the votes cast on the matter were voted in favor of this “say-on-pay” approval. The Board and the Compensation

Committee considered the voting results and high level of stockholder support when establishing our executive compensation programs for fiscal 2026 and implemented an executive compensation program for fiscal 2026 that was substantially similar to the program in place for fiscal 2025.

The Compensation Committee has the authority to retain independent advisors to assist it in the compensation-setting process and receive funding to engage such advisors. The Chair of the Compensation Committee, in consultation with other Compensation Committee members, defines the scope of any advisor’s engagement and related responsibilities.

The Compensation Committee engaged Compensation Strategies, Inc. (“Compensation Strategies”) for fiscal 2026 to assist in a review of the company’s executive compensation program and the executive compensation practices at a peer group of companies. The compensation consultants from Compensation Strategies have no other direct or indirect business relationships with us. The Compensation Committee has assessed the independence of Compensation Strategies and concluded that its engagement of Compensation Strategies does not raise any conflict of interest with the Company or any of its directors or executive officers.

As noted above, the Compensation Committee selects a peer group of companies each year with input from its independent compensation consultant to help evaluate our executive compensation program. In May 2026, the Compensation Committee identified the following companies as the peer group for fiscal 2027:

In selecting the peer group for fiscal 2027, the Compensation Committee considered public companies with a thematic fit with the Company’s business and targeted a group of about 20 companies with the Company’s revenue at approximately the 50th percentile of the group.

Our Compensation Committee utilizes three main components for executive officer compensation: base salary, a cash incentive bonus, and long-term equity-based awards. Our compensation program is designed to balance our need to provide our executive officers with incentives to achieve our short- and long-term performance goals with the need to pay competitive base salaries.

There is no pre-established policy for allocating between cash and non-cash or short-term and long-term compensation. In determining the allocation each year among base salary, annual cash incentive bonus, and long-term equity-based awards, the Compensation Committee considers our short-term and long-term business objectives, competitive trends within our industry, and each named executive officer’s current and prior compensation.

An important guiding principle for our executive compensation program is our belief that it benefits our stockholders for executive management’s compensation to be tied to our short-term and long-term performance, so that a significant portion of each executive officer’s compensation is tied to the achievement of our goals and objectives. As a result, “at risk” compensation makes up a significant portion of our executives’ compensation.

Base salaries for our executive officers are set with regard to a number of factors, including the executive’s title and responsibilities within the Company, the executive’s performance in recent periods, the executive’s potential for continued development within the organization, an assessment of the base salaries of similarly situated executives with the peer group companies noted above, and internal parity with other executives. The base salary levels for each executive officer, and any increases or decreases to those levels, are reviewed and approved each year by the Compensation Committee.

In fiscal 2026, the base salaries for our named executive officers were as follows:

Our Compensation Committee believes that annual performance-based cash bonuses play an important role in providing incentives to our executive officers to achieve annual performance goals. To that end, we have established an annual cash bonus program (the “Bonus Program”) in order to align executives’ goals with our financial, strategic and tactical objectives for the current year.

Selected employees, including all of our named executive officers, are eligible to participate in the Bonus Program. Each participant in the Bonus Program is assigned a target annual cash bonus, generally expressed as a percentage of the participant’s base salary, the payment of which is conditioned on the achievement of certain performance goals and objectives established by the Compensation Committee. Bonuses paid under the Bonus Program, if any, may be based upon achievement of fiscal year performance goals.

The Compensation Committee generally sets the corporate performance goals at “target” levels the Compensation Committee believes are challenging, but reasonable, for management to achieve, with reduced or increased bonus opportunities for performance below or above, as the case may be, the targeted level. The Compensation Committee may also establish a maximum aggregate amount of bonuses that all participants will be eligible to receive during a Performance Period based on performance results for the fiscal year as it may determine. If the bonus pool for a Performance Period is insufficient to fully fund the bonuses earned during the Performance Period, each participant’s bonus is ratably reduced.

At the end of each Performance Period, the Compensation Committee determines the level of Company achievement with respect to the specified goals. The Compensation Committee retains discretion to make appropriate adjustments to the performance goals for the effects of events that were not anticipated in establishing the performance goals, to exclude one-time or non-recurring expenses in calculating achievement of performance goals, and to make other adjustments to the bonuses (e.g., individual adjustments based on evaluation of each participant’s performance during the Performance Period) that otherwise would be payable based on actual performance. Final bonus levels are then based on those determinations and generally paid to the executives in the quarter following the completion of a Performance Period.

For fiscal 2026, the Compensation Committee determined that annual bonuses would be based on achievement of specified target levels of revenue and non-GAAP EPS, and achievement of strategic Key Operating Drivers. The Compensation Committee selected these measures to incentivize management to drive growth while maintaining a focus on financial performance and execution of the Company’s strategic priorities. Revenue directly measures top-line growth and is a metric that management can communicate to employees throughout the fiscal year, while non-GAAP EPS is intended to ensure that growth is achieved with appropriate attention to profitability. In addition, aggregate bonus payouts are limited to the amount available in the bonus pool, providing additional financial discipline by constraining payouts even if performance against the applicable metrics would otherwise result in higher aggregate bonus payments. The strategic Key Operating Drivers allow the Compensation Committee to further incentivize management’s execution of specific initiatives that it believes are important to the Company’s growth and long-term performance.

If, at the end of the first two quarters of fiscal 2026, the Company was on pace to achieve a bonus level payout for the fiscal year, the Compensation Committee could approve a partial bonus payment of up to 50% of the projected annual bonus opportunity amount for the year (with the final bonus to be awarded at the end of the fiscal year to be reduced by the amount of any such partial payment).

For fiscal 2026, bonuses under the Bonus Program were based 45% on revenue, 45% on non-GAAP EPS and 10% on achievement of strategic Key Operating Drivers, with total payouts capped at 200% of target. Aggregate bonus payouts were also limited to the amount available in the fiscal 2026 bonus pool.

For fiscal 2026, the revenue performance target for purposes of the Bonus Program was $124.5 million, corresponding to a payout equal to 100% of the target bonus opportunity. Revenue of $119.5 million, representing 96%

of the target, was the minimum performance threshold for a payout and would result in a payout equal to 75% of the target bonus opportunity. No payout would be earned for revenue below $119.5 million. Payouts would increase linearly between the specified performance levels as follows:

For fiscal 2026, the non-GAAP EPS performance target for purposes of the Bonus Program was $0.16 per share, corresponding to a payout equal to 100% of the target bonus opportunity. Non-GAAP EPS of $0.13 per share was the minimum performance threshold for a payout and would result in a payout equal to 75% of the target bonus opportunity. No payout would be earned for non-GAAP EPS below $0.13 per share. Payouts would increase linearly between the specified performance levels as follows:

The Key Operating Drivers included strategic objectives relating to growth initiatives, new product development and commercialization, and operational execution.

The Compensation Committee established the following target and maximum bonus amounts set forth below for the named executive officers under the Bonus Program.

In August 2026, the Compensation Committee determined that the Company’s fiscal 2026 performance against the revenue, non-GAAP EPS and Key Operating Driver measures resulted performance equal to approximately 86.6% of target. However, the terms of the Company’s annual bonus program also limit aggregate payments to the amount accrued in the fiscal 2026 bonus pool. Because the accrued pool supported payments equal to 80% of each participant’s target opportunity, and the Compensation Committee and Board determined not to authorize additional funding, final payments were limited to 80% of target. This decision reflected the Company’s commitment to financial discipline and ensured that cash incentive payments did not exceed the amount funded under the program.

Fiscal 2027 targets. The Compensation Committee established the fiscal 2026 performance targets against the backdrop of a significant transition in the Company’s business following the winding down of a major customer deployment that had represented approximately 25% of the Company’s revenue in fiscal 2024. During fiscal 2025, the Company implemented restructuring initiatives and reductions in operating expenses as it resized and refocused its operations. Fiscal 2026 represented a reset year for the Company following the restructuring and the roll-off of this significant customer deployment. The threshold target established by the Compensation Committee reflected the Company’s transition from the prior customer-deployment concentration and restructuring period to a normalized

operating base, while accounting for material uncertainty related to tariffs, supply-chain conditions, international trade, and customer demand. Achievement of the minimum thresholds required management to execute against the operating plan and deliver performance within a defined range in view of these risks.

With the Company’s normalized revenue and operating base established in fiscal 2026, the Compensation Committee established fiscal 2027 performance goals designed to require growth from that base. The minimum performance thresholds and target levels for the applicable fiscal 2027 performance awards require improvement over the corresponding fiscal 2026 results. Accordingly, achievement of even the minimum payout thresholds requires year-over-year growth. This approach reflects the Company’s transition from fiscal 2026 reset-year objectives to fiscal 2027 growth-based objectives.

Types of Awards. A core feature of our long-term incentive program is the award of PSUs. PSUs vest based on Company performance and the executive’s continued service through the vesting period. We currently use two types of PSUs: (i) Financial PSUs that vest based on total revenue and non-GAAP EPS performance targets, and (ii) Relative TSR PSUs that vest based on our total shareholder return relative to the Russell Microcap Index over a three-year period. In addition, we also grant RSUs that vest based solely on continued service, providing a retention incentive regardless of stock price performance. The Compensation Committee reviews the mix of equity award types annually and may adjust the program to strengthen alignment with stockholder interests.

As noted above, the Compensation Committee believes revenue and non-GAAP EPS (determined consistent with the approach used for reporting “Non-GAAP EPS” in our quarterly earnings releases) to be good indicators of our success, given the market in which we compete. In addition, they are metrics that management can calculate and communicate to employees. Using growth in total revenue as a performance measure in our PSUs incentivizes management to grow our existing business and aligns with our strategy of growth through acquisitions. We use non-GAAP EPS because we believe the adjustments we make to our EPS for purposes of our incentive programs provide a more accurate picture of the value of our company than EPS computed in accordance with GAAP. In particular, we believe it is appropriate to exclude non-cash accounting charges for amortization of intangible assets (other than goodwill) from EPS as we believe our value, and the value of the companies in our industry we acquire, is not in the tangible property we own, but rather in the design and development of products which we then have other people build for us. As such, we believe deducting a non-cash expense from earnings would under-represent our core profitability.

For fiscal 2026, the Compensation Committee determined that annual equity awards for our named executive officers would be allocated one-quarter to Financial PSUs, one-quarter to Relative TSR PSUs, and one-half to RSUs (allocated based on the total dollar value of the award approved for the executive by the Compensation Committee).

Grant of Fiscal 2026 Financial PSU Awards. In July 2025, the Compensation Committee approved an award of Financial PSUs to each of the named executive officers with the target number of Financial PSUs subject to these awards as follows: Mr. Awsare – 86,136 Financial PSUs, Mr. Stringham – 51,167 Financial PSUs, and Mr. Gurusamy – 42,494 Financial PSUs. The target number of Financial PSUs subject to each award was determined by dividing a dollar amount determined by the Compensation Committee by $2.407, the average closing price of our common stock over the last 30 trading days before July 1, 2025.

The vesting of each award is subject to the Company’s performance over fiscal 2026 (as well as the executive’s continued employment with the Company through the vesting dates), with one-third of the number of Financial PSUs that are earned for the award based on the Company’s performance during fiscal 2026 vesting on the data the Compensation Committee determined the performance levels achieved and the remaining earned PSUs vesting over 8 consecutive quarters thereafter. Any PSUs that are not earned based on performance during fiscal 2026 are cancelled without vesting. The percentage of the target number of Financial PSUs that are earned is determined based on both the Company’s revenue (50%) and the Company’s non-GAAP EPS (50%) for the performance period. In no event will an award vest more than 200% of the target number of Financial PSUs subject to the award.

When it approved these grants in July 2025, the Compensation Committee set the fiscal 2026 revenue target at $124.5 million, with the following payout levels (and linear interpolation between levels):

When it approved these grants in July 2025, the fiscal 2026 non-GAAP EPS target was $0.16 per share, with the following payout levels (and linear interpolation between levels):

In August 2026, the Compensation Committee determined that the Company’s fiscal 2026 revenue of $120.9 million resulted in an 82% payout for the revenue component and fiscal 2026 Non-GAAP EPS of $0.15 resulted in a 91.7% payout for the Non-GAAP EPS component. Based on the 50% weighting of each performance measure, each named executive officer earned 86.85% of the target number of shares subject to the award, with one-third of the earned shares vesting immediately and the remaining earned shares vesting in equal installments over the following eight quarters through June 1, 2028.

Grant of Fiscal 2026 Relative TSR PSU Awards. In July 2025, the Compensation Committee approved an award of Relative TSR PSUs to each of the named executive officers, with the target number of TSR PSUs subject to these awards as follows: Mr. Awsare – 86,136 Relative TSR PSUs, Mr. Stringham – 51,167 Relative TSR PSUs, and Mr. Gurusamy – 42,494 Relative TSR PSUs. The target number of Relative TSR PSUs subject to each award was determined by dividing a dollar amount determined by the Compensation Committee by $2.407, the average closing price of our common stock over the last 30 trading days before July 1, 2025 (the last 30 trading days of the last full fiscal quarter prior to the quarter in which the grant was made).

The vesting of each award will be determined solely based on the Company’s TSR for the three-year period commencing on July 1, 2025, relative to the TSRs for the companies in the Russell Microcap Index for that three-year period, with the award vesting as 50% of the target number of TSR PSUs if the Company’s relative TSR for the three-year period is at the 50th percentile and 200% if the Company’s relative TSR for the three-year period is at the 75th percentile or higher. If the Company’s relative TSR for the three-year period is between the 50th percentile and the 75th percentile, the vesting percentage will be determined by linear interpolation between the 50% and 200% levels, and no portion of the award will vest if the Company’s relative TSR for that period is below the 50^th percentile. Vesting is also contingent on continued employment with the Company through the applicable vesting date. None of the fiscal 2026 Relative TSR PSU Awards vested during fiscal 2026 as performance is measured over the entire three-year performance period of the award.

Grant of Fiscal 2026 RSU Awards. In July 2025, the Compensation Committee approved an award of RSUs to each of the named executive officers, with the number of RSUs subject to these awards as follows: Mr. Awsare – 172,272 RSUs, Mr. Stringham – 102,336 RSUs, and Mr. Gurusamy – 84,989 RSUs. The number of RSUs subject to each award was determined by dividing a dollar amount determined by the Compensation Committee by $2.407, the average closing price of our common stock over the last 30 trading days before July 1, 2025. Each grant vests as to one-third of the RSUs on July 11, 2026 and the remaining two-thirds of the RSUs quarterly thereafter beginning on September 1, 2026 (so that the RSUs will be fully vested on June 1, 2028).

Vesting of Fiscal 2025 Financial PSU Awards. During fiscal 2025, the Compensation Committee approved awards of Financial PSUs to Mr. Awsare and Mr. Gurusamy that vest based on the Company’s performance over each of fiscal 2025, fiscal 2026 and fiscal 2027 (as well as the executive’s continued employment with the Company), with one-third of the target number of Financial PSUs for the award allocated to fiscal 2025, one-third of the target number of Financial PSUs for the award allocated to fiscal 2026, and one-third of the target number of Financial PSUs for the award allocated to fiscal 2027. If the financial metrics for the specific year are not met, then the shares attributable to that year can no longer be subject to vesting. The percentage of the target number of Financial PSUs that vest for each performance period is determined based on both the Company’s revenue compound annual growth rate (“Revenue CAGR”) for the applicable period and the Company’s non-GAAP EPS compound annual growth rate (“Non-GAAP EPS CAGR”) for the performance period (with the Company’s revenue and non-GAAP EPS for each performance period measured against the results for the immediately preceding fiscal year). In no event will an award vest more than 200% of the target number of Financial PSUs subject to the award. The target number of Financial PSUs for the named executive officers were as follows: Mr. Awsare – 69,894 Financial PSUs and Mr. Gurusamy – 20,005 Financial PSUs.

In August 2026, the Compensation Committee determined that the Company’s Revenue CAGR for fiscal 2026 and the Company’s Non-GAAP EPS CAGR for fiscal 2026 were both below the threshold performance level established for these awards. Accordingly, no portion of the Financial PSU awards granted to the named executive officers in fiscal 2025 vested for the fiscal 2026 performance period.

Vesting of Mr. Awsare’s New-Hire Financial PSU Award During Fiscal 2026. During fiscal 2024, the Compensation Committee approved an award of 229,529 PSUs to Mr. Awsare as an inducement to him to commence employment with the Company, provide long-term retention incentives, and further align his interests with those of our stockholders. The number of shares subject to this award was determined by dividing a dollar amount specified in Mr. Awsare’s employment agreement ($1,025,000 for the target number of PSUs) by the average of the closing prices for a share of the Company’s common stock over the thirty consecutive trading days prior to Mr. Awsare’s start date with the Company. The vesting of the PSU award (with a target number of 235,127 shares) is subject to the Company’s performance over each of fiscal 2024, fiscal 2025 and fiscal 2026 (as well as the executive’s continued employment with the Company), with 16% of the target number of PSUs for the award allocated to fiscal 2024, 42% of the target number of PSUs for the award allocated to fiscal 2025, and 100% of the target number of PSUs for the award allocated to fiscal 2026 (and with the number of PSUs vested for fiscal 2025 and fiscal 2026 to be reduced by any PSUs that vested for a prior fiscal year). The award vests based on the Company’s Revenue CAGR and Non-GAAP EPS CAGR performance for the applicable fiscal year (with the vesting percentage for the portion of the award allocated to fiscal 2026 subject to adjustment based on the Company’s TSR for the entire three-year period covered by the award relative to the TSRs for the companies in the Russell Microcap Index for that period).

In August 2026, the Compensation Committee determined that the Company’s Revenue CAGR for fiscal 2026 and the Company’s Non-GAAP EPS CAGR for fiscal 2026 were both below the threshold performance level established for the award. Accordingly, no portion of Mr. Awsare’s Financial PSU award granted in fiscal 2024 vested for the fiscal 2026 performance period.

Grant of Fiscal 2027 Equity Awards. In July 2026, the Compensation Committee approved the fiscal 2027 awards for our named executive officers, including approximately 41% RSUs, 38% Financial PSUs, and 21% TSR PSUs. The Financial PSUs include a first award that vests over a three-year period based on growth in the Company’s revenue (50%) and non-GAAP EPS (50%) during fiscal 2027 and the executive’s continued employment through the three-year vesting period, and a second award that vests over a three-year period based on growth of the Company’s unmanned systems revenue. For fiscal 2027, the Compensation Committee established minimum revenue and non-GAAP EPS performance thresholds for the first award of Financial PSUs that require performance above the Company’s corresponding fiscal 2026 results. The Compensation Committee believes these performance levels establish an appropriate balance between challenging management to deliver growth and maintaining achievable incentive opportunities.

The Relative TSR PSUs vest based solely on the Company’s TSR for the three-year period consisting of fiscal 2027, fiscal 2028 and fiscal 2029 relative to the TSRs for the companies in the Russell Microcap Index. The RSUs and PSUs (if earned) are scheduled to vest in installments over a three-year period, subject to the executive’s continued employment. The number of RSUs and the target number of PSUs for these awards was determined based on the dollar values approved by the Compensation Committee (allocated for each executive as noted above) and converted into shares using the same methodology as described above for the fiscal 2026 grants. In approving these changes, the Compensation Committee believed they would help align our program more closely with the interests of our stockholders and be a more prudent use of our equity.

Delegation to CEO of Certain Grant Authority. The Compensation Committee has delegated authority to our Chief Executive Officer to grant options and/or RSUs to selected newly-hired employees, other than executive officers and employees directly reporting to the Chief Executive Officer, within certain parameters established by the Compensation Committee. Management reports these new-hire award grants to the Compensation Committee.

All of our executive officers are eligible to participate in our benefits programs offered to our employees generally, which include medical, dental and vision plans, our 2013 Employee Stock Purchase Plan, a 401(k) plan, tuition reimbursement, life insurance and short and long-term disability coverage. In designing our employee benefits program, we seek to provide an overall level of benefits that is competitive with that offered by similarly situated companies in the markets in which we operate based upon our general understanding of industry practices.

The Company makes matching contributions under the 401(k) plan to each plan participant, including our executive officers, in an amount equal to 25% of the first 6% of salary deferred by the participant.

The Company has an executive physical program, under which Mr. Awsare and Mr. Stringham were eligible to be reimbursed during fiscal 2026 up to $2,500 for the costs of an annual executive physical examination. With the exception of this annual executive physical program, it is our policy to not extend significant perquisites to executives that are not broadly available to our other employees, though the Company may provide additional benefits to newly-hired executive officers as an inducement to their joining the Company.

The Company has entered into arrangements with each of the named executive officers to provide severance benefits upon certain terminations of their employment with the Company. These agreements are described in more detail below under “Severance and Change in Control Arrangements with Named Executive Officers.”

In accordance with SEC and Nasdaq requirements, the Board has adopted an executive compensation recovery policy regarding the adjustment or recovery of certain incentive awards or payments made to current or former executive officers in the event that we are required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws. In general, the policy provides that, unless an exception applies, we will seek to recover compensation that is awarded to an executive officer based on the Company’s attainment of a financial metric during the three-year period prior to the fiscal year in which the restatement occurs, to the extent such compensation exceeds the amount that would have been awarded based on the restated financial results.

Section 162(m) of the Internal Revenue Code generally prohibits a publicly-held company from deducting compensation paid to a current or former named executive officer that exceeds $1 million during the tax year. Certain

awards granted before November 2, 2017 that were based upon attaining pre-established performance measures that were set by the Compensation Committee under a plan approved by our stockholders, as well as amounts payable to former executives pursuant to a written binding contract that was in effect on November 2, 2017, may qualify for an exception to the $1 million deductibility limit.

The Compensation Committee notes this deductibility limitation as one of the factors in its consideration of compensation matters. However, the Compensation Committee generally has the flexibility to take any compensation-related actions that it determines are in the Company’s and its stockholders’ best interest, including designing and awarding compensation for our executive officers that is not fully deductible for tax purposes.

Our Compensation Committee structures our executive compensation programs so as to appropriately reward executives for operating performance and growth without undue risk-taking and oversees, among other things, the assessment and management of risks related to the Company’s compensation plans and policies. The Compensation Committee has evaluated our compensation policies and programs and believes that our compensation policies and practices provide appropriate incentives and controls and are not reasonably likely to have a material adverse effect on the Company.

The Board grants equity-based awards to members of senior management and encourages members of senior management to acquire and hold stock in the Company, to further align the interests of the executives with the stockholders. However, neither the Board nor the Compensation Committee has established formal stock ownership guidelines for the executive officers of the Company.

The following table sets forth, for the fiscal years indicated, the compensation paid to our named executive officers:

We have entered into an employment agreement with Mr. Awsare and signed offer letters with each of our other named executive officers, which set forth the salary, bonus, and other compensation terms briefly described below. Provisions relating to outstanding equity incentive awards, if any, and post-termination of employment benefits are discussed in separate sections of this proxy statement. The named executive officers’ salary and target annual bonus levels for fiscal 2026 are described above in this “Executive Compensation” section.

Saleel Awsare. On October 31, 2023, we entered into an employment agreement with Mr. Awsare. The agreement is for no specific term and provides Mr. Awsare is employed at-will. The agreement provides for Mr. Awsare to receive an initial annual base salary of $500,000 and to participate in the Company’s annual bonus plan with an initial target annual bonus opportunity of 100% of his annual base salary, with the actual amount of the bonus to be determined by the Compensation Committee based on actual performance for the year. The agreement also provides for Mr. Awsare to receive a sign-on bonus of $136,000, with one-third of the bonus paid on his starting employment with the Company, one-third of the bonus paid, subject to his continued employment with the Company, six months after his start date, and one-third of the bonus paid, subject to his continued employment with the Company, at the end of fiscal 2024 when annual bonuses would generally be paid to the Company’s executives. In addition, the agreement provides that Mr. Awsare will be entitled to participate in the employee health and welfare and other fringe benefit plans and programs generally available to the Company’s employees. Mr. Awsare would also be entitled to reimbursement of up to $100,000 for expenses incurred if he decides to relocate to Orange County, California (subject to repayment to the Company if his employment terminates within two years after his start date).

Brent Stringham. We entered into an offer letter with Mr. Stringham dated September 14, 2024. The agreement is for no specific term and provides that Mr. Stringham is employed as Chief Accounting Officer and Interim Chief Financial Officer on an at-will basis. The agreement provides for an initial annual base salary of $267,000, subject to periodic review. The agreement also provides that Mr. Stringham will be entitled to participate in the Company’s annual bonus plan with an initial target annual bonus opportunity of 40% of his annual base salary, with the actual amount of the bonus to be determined by the Compensation Committee based on actual performance for the year. The agreement also provides for Mr. Stringham to receive a retention bonus of $100,000, paid on the first anniversary of the commencement date, subject to his continued employment with the Company. On January 6, 2025, Mr. Stringham’s offer letter was amended to reflect his promotion to Chief Financial Officer, along with an adjustment to his annual base salary to $310,000 and bonus target to 50%. Mr. Stringham’s offer letter was further amended on January 1, 2026, to reflect that his annual base salary was increased to $375,000.

Mathi Gurusamy. We entered into an offer letter with Mr. Gurusamy dated April 2, 2024. The agreement is for no specific term and provides Mr. Gurusamy is employed at-will. The agreement provides for an initial annual base salary of $330,000, subject to periodic review. The agreement also provides that Mr. Gurusamy will be entitled to participate in the Company’s annual bonus plan with an initial target annual bonus opportunity of 50% of his annual base salary, with the actual amount of the bonus to be determined by the Compensation Committee based on actual performance for the year. The agreement also provides for Mr. Gurusamy to receive a sign-on bonus of $50,000, with one-half of the bonus paid on his starting employment with the Company and the remainder of the bonus to vest and be paid, subject to his continued employment with the Company, six months after his start date. In addition, the agreement provides that Mr. Gurusamy will be entitled to participate in the employee health and welfare and other fringe benefit plans and programs generally available to the Company’s employees. On April 1, 2025, Mr. Gurusamy was promoted to the position of Chief Product and Strategy Officer and his annual base salary was increased to $375,000. Mr. Gurusamy’s offer letter was amended on April 1, 2025 to reflect the promotion and salary adjustment. On August 26, 2026, Mr. Gurusamy’s offer letter was amendment effective August 1, 2026, to reflect that his annual base salary was

increased to $390,000 and to provide that the restriction on the severance provision of the agreement (which had provided for severance only upon a qualifying termination within two years after Mr. Gurusamy’s start date with the Company) will no longer apply.

The following table provides information concerning outstanding stock awards held by our named executive officers as of June 30, 2026. Our named executive officers did not hold any outstanding options as of that date.

Although we do not have fixed term employment agreements with any of our employees, the named executive officers are each a party to an agreement with the Company that provides cash payments and acceleration of equity awards in certain circumstances that result in termination of employment. These agreements are intended to encourage retention and to align executive and stockholder interests by enabling executives to consider corporate transactions that are in the best interests of the stockholders and other constituents of the Company without undue concern over whether the transactions may jeopardize the executives’ own employment.

Mr. Awsare’s employment agreement with the Company provides that if his employment is terminated by the Company without Cause or by Mr. Awsare for Good Reason (as such terms are defined in the agreement), Mr. Awsare will be entitled to receive the following separation benefits: (1) one times his annual base salary paid out in installments over the year following his separation date; (2) payment of any incentive bonus due for a fiscal year that ended prior to his separation date plus 100% of the target amount of the incentive bonus for the fiscal year in which the separation date occurs; (3) payment or reimbursement of premiums to continue healthcare coverage under COBRA for Mr. Awsare and his eligible dependents for up to 12 months; (4) as to each then-outstanding equity-based award granted by the Company to Mr. Awsare that vests based solely on continued service with the Company and unless otherwise expressly provided in the applicable award agreement, accelerated vesting of any portion of the award that is scheduled to vest within one year after Mr. Awsare’s separation date; and (5) as to each outstanding equity-based award granted by the Company to Mr. Awsare that is subject to performance-based vesting requirements and unless otherwise expressly provided in the applicable award agreement, Mr. Awsare’s employment with the Company will be deemed to have continued for one year after his separation date.

However, if Mr. Awsare’s employment is terminated by the Company without Cause or by Mr. Awsare for Good Reason during the period beginning 60 days before the closing of a change in control of the Company (or, if earlier, on the date a definitive agreement is entered into to effect the change in control transaction) and ending on the second anniversary of the change in control transaction, Mr. Awsare will be entitled to receive the following separation benefits: (1) two times his annual base salary paid out in installments over the two years following his separation date; (2) payment of any incentive bonus due for a fiscal year that ended prior to his separation date plus 200% of the target amount of the incentive bonus for the fiscal year in which the separation date occurs; (3) payment or reimbursement of premiums to continue healthcare coverage under COBRA for Mr. Awsare and his eligible dependents for up to 24 months; (4) as to each then-outstanding equity-based award granted by the Company to Mr. Awsare that vests based solely on continued service with the Company and unless otherwise expressly provided in the applicable award agreement, accelerated vesting of the entire outstanding and unvested portion of the award; and (5) as to each outstanding equity-based award granted by the Company to Mr. Awsare that is subject to performance-based vesting requirements and unless otherwise expressly provided in the applicable award agreement, any service-based vesting requirement under the award will be deemed satisfied in full but the performance-based vesting measurement will still apply and will be treated as provided in the applicable award agreement.

Mr. Awsare’s right to receive the severance benefits described above is subject to his executing and not revoking a general release of claims in favor of the Company. Should benefits payable to Mr. Awsare trigger excise taxes under Section 4999 of the Code, Mr. Awsare would either be entitled to the full amount of his benefits or, if a cut-back in the benefits would result in greater net (after-tax) benefit to Mr. Awsare, the benefits would be cut-back to the extent necessary to avoid such excise taxes.

Under their offer letters described above, Mr. Stringham and Mr. Gurusamy are eligible to receive severance payments if their employment is terminated either by the Company without Cause or by the executive for Good Reason, in each case as defined in the offer letter. The severance for each executive would consist of a lump sum payment equal to 6 months of the executive’s annual base salary plus an amount equal to 50% of the amount of bonuses (if any) earned by the executive during the 12 months preceding termination.

In addition, the offer letters for Mr. Stringham and Mr. Gurusamy provide that if the executive’s employment is terminated by us without Cause or by the executive for Good Reason within 60 days prior to or 12 months following a Change in Control (as defined in the offer letter), (i) all of the executive’s outstanding equity awards will accelerate and become fully vested; (ii) the executive will receive a cash severance payment in a lump sum (in lieu of the cash severance benefit described in the preceding paragraph, if applicable) equal to 12 months of his annual base salary plus an amount equal to 100% of his target annual bonus opportunity; and (iii) the executive and his eligible dependents will be entitled to continued participation in the Company’s group health, dental and vision insurance plans on the same terms as existed at the time of his termination for up to 12 months thereafter.

The executive’s right to receive the severance benefits described above is subject to his executing and not revoking a general release of claims in favor of the Company. Should benefits payable to the executive trigger excise taxes under Section 4999 of the Code, the executive will either be entitled to the full amount of his benefits or, if a cut-back in the benefits would result in greater net (after-tax) benefit to the executive, the benefits will be cut-back to the extent necessary to avoid such excise taxes.

The award agreements for annual grants of financial PSUs to our executive officers (and inducement grants to newly-hired executives with similar performance metrics) generally provide that if a change in control occurs, the performance period of the award will end, and the vesting of the award for performance periods that have not been completed will be determined based on our performance through the end of the fiscal quarter prior to the quarter in which the change in control occurs (with the performance targets being pro-rated to reflect the shortened performance period) or, if greater, the target performance level, while the award agreements for relative TSR PSUs granted to our executive officers generally provide that the vesting of the award will be determined based on relative TSR performance through the date of the change in control. In each case, the award will remain subject to the time-based vesting requirements, provided that if the executive’s employment is terminated by us without cause, by the executive for good reason, or due to the executive’s death or disability, in any case within 60 days prior to or at any time following the change in control (or if the award is not assumed or continued by the acquiring or successor entity), the time-based vesting requirements will be deemed satisfied. In addition, if the executive’s employment terminates due to death or disability (other than in the context of a change in control), the vesting of the award for the performance period in which the termination date occurs will be determined at the end of that performance period (or, in the case of relative TSRPSUs, at the time of the termination), and any time-based vesting requirements for that performance period (and any prior performance period under the award) will be deemed satisfied.

The award agreements for the inducement grants of Relative TSR PSUs to Mr. Awsare and Mr. Gurusamy in connection with their joining the Company during fiscal 2024, generally provide that if a change in control occurs, the three-year performance period of the award will end on the change in control date, and the vesting of the award will be determined based on the closing price of our stock on the last trading day prior to the change in control. The award will remain subject to the time-based vesting requirements, provided that if the executive’s employment is terminated by us without cause, by the executive for good reason, or due to the executive’s death or disability, in any case within 60 days prior to or at any time following the change in control (or if the award is not assumed or continued by the acquiring or successor entity), the time-based vesting requirements will be deemed satisfied. In addition, if the executive’s employment terminates due to death or disability (other than in the context of a change in control), the vesting of the award will be determined based on our relative TSR as of the executive’s termination date, and the time-based vesting

requirements will be deemed satisfied. If, during the performance period and more than 12 months after the grant date (other than in the context of a change in control), the executive’s employment is terminated by us without cause or by the executive for good reason, the vesting of the award will be determined based on our relative TSR as of the executive’s termination date and the time-based vesting requirements will be deemed satisfied, provided that the portion of the award that vests will be pro-rated based on the portion of the performance period that has elapsed as of the termination date.

The executive’s right to receive the benefit of the vesting provisions described above is subject to his executing and not revoking a general release of claims in favor of the Company.